""
""
""
""
""
""
""
""
""
""
""
""
""
""
""
""
""
,Link,Biomarkers,Diseases,Pathways,Clinical_Trials,Drugs,ClinicalTrialsTitle,Alteration_Groups
c76e588f-080a-5f4e-a338-955130da287d,https://www.mycancergenome.org/content/gene/tp53/,TP53," Cancer, Vaginal Carcinoma, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Neuroblastoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Transitional Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Large Cell Lung Carcinoma, Clear Cell Renal Cell Carcinoma, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Acute Lymphoblastic Leukemia, Vulvar Carcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Hepatocellular Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Pancreatic Ductal Adenocarcinoma, Lymphoma, Malignant Peritoneal Neoplasm, Malignant Bladder Neoplasm, Benign Fibrous Histiocytoma, Malignant Head and Neck Neoplasm, Acute Myeloid Leukemia, Malignant Solid Tumor, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Breast Ductal Carcinoma, Anal Carcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Fallopian Tube Neoplasm, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Colon Neuroendocrine Neoplasm, Histiocytic And Dendritic Cell Cancer, Urothelial Carcinoma, Malignant Ovarian Epithelial Tumor", Cell cycle control, 206, 3,"[['8920c079-a6c0-5fa5-b5f0-aadce7ec0867', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['559d2f86-2a79-5e97-8b86-cbf90fa17ba6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['b0b04d8b-edba-56eb-9e00-1b5a069e185c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['c927ab37-1d1d-5755-a154-c18253fd367c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['686de7ed-a069-5fbb-9d0b-849398d393d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['97d2d07b-8fb4-55a5-8fae-682c4a5a091b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['1d8ef049-8e73-57c1-a414-127323b655d8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['edeb4236-f82c-56ac-b5bb-a7b247a407d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['81d544bf-76fa-5126-8bc4-ae12ff849510', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['2891c7b5-4548-5bc3-8cc1-ce2024027b6c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['428ca4a8-a020-51fe-8ed8-d1ee814d4a6f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor'], ['ef049a6e-21af-54d6-b69f-cfc4ab9b484c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['f876db17-7031-590a-80b8-f05f6b93cc07', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['3c6ec96c-d51b-53d2-b5e7-abd3106c6254', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['d0a1923a-945e-5758-bad0-7d964e2242f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['47faa36b-f117-52a2-a0c7-4a748fa30bfa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['0634f789-b86b-571a-922b-51d066058198', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['37ae8aef-3ce7-5a6a-8f0d-37c04d0c9b32', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['f435a5bb-177c-5d46-b831-b10d177b9d8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['bc6695f6-352a-5dd5-94b6-5b9dc00fd71a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2efa4aac-8164-5bff-a495-6626467a2375', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['8104b769-6031-50d3-b783-7379c93cd6c0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['7ac4e91c-40fa-5342-b988-2af33f945e67', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['77e2ffd3-7719-58e6-a1f5-3759cf00b74e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['aa95ff76-4526-5f44-8e9a-61d09c518749', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['555105c4-6ee2-5266-904d-244146ba85dd', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['1e6a42d4-1d17-5c82-8efd-a17d01604406', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a26b4e11-e0b1-5036-978d-8465070587cb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3da6e26f-c7ec-5113-805b-80b7302eae6b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['f1e66d04-9749-5f61-97d1-424ae2704448', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['8290b969-52fd-5ab6-a2a3-1dd845c68233', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a27cb61-7185-5eaa-b87b-ae2ba0387fa6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['ae756cad-e710-556d-b5ef-5e22ca23ae04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d0a5d9a6-03a3-5abd-a01f-92a1e71e0984', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['cfe127b9-93ba-5b83-986a-5a2a6ecca130', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['ddc6a312-3031-53c5-965e-94ac74f8b6aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['403dc844-4a13-5dc9-8d44-8bc4aaa0ffb1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['0adf2c15-fc9b-5c1e-8a0d-2b60253f9b4d', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['cf8e4c89-da0d-5e84-97dd-c0f4646a4166', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['526098fa-0c19-5bac-b9ec-1d29111862ab', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e51fc27a-baaa-58b8-8df6-6c5b2f8d984c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['4d3e8616-9c78-5e7c-a1cd-393769c71c90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['df545b25-510a-5a03-882f-6026d5665f0b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['9b29392c-b012-51ea-88bc-4a024dfc2c07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma'], ['f94ad441-3d98-53ac-a220-858c6ea23745', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c3c0333f-9623-53d2-bd07-3558d3ad0247', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['d7166f7a-728e-5550-82f1-b6c76863f2aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss,', ' Medulloblastoma'], ['6e6afa2f-0af9-5d89-80fe-3442ce365909', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['b37fb9cc-bf33-5e4a-8c7f-1284f96e0926', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['f25dfe3b-b863-5ca3-96e0-a07dc5aa7dd4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK,', ' Acute Myeloid Leukemia'], ['7c6bd3fa-b534-5f32-913c-13efe09a988c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['46d8d3b9-c1ba-505c-8c0b-277178274475', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift,', ' Myelodysplastic Syndromes'], ['23ba20e7-a04f-5f1e-b7c3-05a463a80d4c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['5395e287-c588-5e7d-9705-05cf7638f0be', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['2857f779-7074-5887-9fb5-17ee5d67ea79', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['8476f372-4407-577a-a1e5-10066857162e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['ed558021-a193-5cd4-a0f1-2dfec163d38e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma'], ['12d2c9ee-8d91-574a-97ee-8c3ac141e289', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['7d56363c-3ca4-5237-a7c7-cb9d80ae5608', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['4b4e37a4-3dcb-5af1-9205-88e209220850', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts']]",
eba36364-821f-5f60-b93e-4857edc625ee,https://www.mycancergenome.org/content/alteration/tp53-loss/,TP53 Loss," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Ovarian Serous Tumor, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Malignant Bladder Neoplasm, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 187, 0,"[['e221663b-5a35-5781-bbd3-acada7f46f8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['75cd3142-59f8-5caf-adab-dad872fbc7f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['7c32e385-22e4-5688-819c-4219039fda73', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['507a6b75-20dd-5e8d-abb2-b8196882db5c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['762c33e0-037f-553d-b2b4-c73d4af3b9d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['ca08e81b-64ec-5e41-b861-3d109aaed50a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4b2e40ed-67de-5c6c-9834-d80205751186', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['1f4561b8-5862-59fe-a960-ee52834e42c3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['c64afea7-5389-5d3a-98f7-0d22257d5bad', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['58779054-877f-5d9e-a552-42ecde884ed0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['35a2a8e4-de0f-59af-b5dd-f26637c7c010', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6b268729-eb67-5362-bb67-d48a43d0e20e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a4621e3f-3a6e-51bd-9cd6-117a397a7a03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['19f47721-6769-514d-9ce5-a8647c3c7258', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['69481b88-9661-5764-9f6e-ff06e1afbca5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['2636aeed-9b11-55de-888e-4840f09a44df', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['2e51066e-ca32-5524-83a2-0f6ff1cd1cd6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['82575ecc-4aeb-5cdb-b9ce-aac82265f105', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['c0c1e6c1-eac2-5830-a7f1-2af3091f8b99', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5ef759a2-1f77-5835-a0a4-a9bd3ae96f03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['9063a22a-c9e8-5ed5-a226-f08e49d1be47', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['6fbe5e54-7397-5c5a-afa2-b5f980f4d677', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['30396263-e633-5e5b-b2f9-e36d15940e39', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c53a462b-1d08-54f5-bb73-df53c3f7caf5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['62d5ae16-1908-5a7d-93c4-adf601d0148f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a2d4906-7ff2-52da-aa03-879b446eb5d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a3c95bdb-87df-5825-bcf4-3d547ca4a9b1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['5a92b405-dcbc-5857-bd97-16d00864c6fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['d6153efa-d93e-5939-9290-a4fddd864cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['4153cbc8-adb3-556b-a0ea-195e9a842928', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['6c369150-0ca4-5ea1-8c34-0efaea36c614', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d8777ca4-4beb-59d6-97df-02633de11587', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['1e8bd600-5a56-54a2-9f95-861a142ea82f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['510aaf02-415b-58c8-b95b-a6ed6e122e68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4c8949f0-9984-5c33-a764-737c02d3d529', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['24ba6965-b932-5e56-a39d-7c688648f3d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f7b4e5ac-0098-50ef-a807-85c14ad681c2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['92f18279-c687-5cc4-b720-47734b22ae3f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f4aa0065-93a7-582f-b025-98d3908c5a94', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['f5ffe9a2-2a95-5e84-8469-51090a0449a1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['f001c121-0641-5df9-81ce-a209ccbdcb07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['251b9e77-7989-55ff-b71a-12c3a0c97083', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3e54bc33-a75f-50a6-9a3f-699b9c7f6685', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4caa5049-8cfd-5822-95dd-80adf34b8341', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss,', ' Medulloblastoma'], ['6ceb47fd-d396-5eca-b527-ea6c61e2119b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['c63b1222-783c-578f-bf08-2290574e900b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['179a8789-afeb-5502-a57a-770cbf30db55', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK,', ' Acute Myeloid Leukemia'], ['81bff8b8-6fac-5a5c-8e81-27395eea14bc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['885d536c-f17f-5837-b8fa-ce13bcc4992f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['4d1b46b7-1239-5840-b608-4590bfc2178e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['d373e6e1-5bd3-5f83-8b42-799026988bf1', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['f596dded-3c13-54d2-afcc-5940bfac2c69', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['46854f60-ad43-51de-9af3-25d368ee1488', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['020c7ed4-e01c-543b-b728-62c2768fdb51', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['2c32d193-1165-5ad8-9dbb-303619d8a194', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['a67abb46-6efa-5c25-978c-90b72f708423', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['583c481f-5151-5f2c-af2c-82a6fb53c0d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['21d7eab8-2c4d-5418-976f-4f2a2c800b1b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['316a53ff-e67c-57e5-a376-357b288d5bb7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['0d2eeb41-053d-5aa6-b0ac-a82c1e023a3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), ELN Adverse Risk Group, Medulloblastoma, SHH-Activated"
0abac394-06e2-5d38-8845-8aca7485d7b5,https://www.mycancergenome.org/content/alteration/tp53-mutation/,TP53 Mutation," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Myeloid Sarcoma, Neuroblastoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Benign Fibrous Histiocytoma, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Colorectal Neoplasm, Gastric Carcinoma, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 175, 0,"[['f7b78afe-1dc1-544b-86ca-fc303608fe12', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['3a06b6c1-b916-585e-a8ee-bf0d44603555', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['d401d6ac-02de-5e98-9416-db7a5d609cae', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['11bbc0c7-e808-5c5b-b9a4-34854b768042', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['ecfb2c62-17f7-5a23-b492-04243f363a68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['50a3a24a-ffba-56d3-b0f4-dd00e66878f5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['144034da-587c-5a5c-91b8-88ba48987da8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['16bf36af-4f2b-51ae-a6b8-b1a112e0d541', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['92dbd658-5154-5f7c-bdac-452374dadf04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['4c48bf2b-8585-59aa-84c1-fed10995262c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['41d02d3c-8e93-5775-bc6d-2ba1db0df6b0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a9a7590f-c952-5fa5-899a-8d504e6636a6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['a778f5c1-738a-5249-b3e5-e2dfc385fc21', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['bceb75d4-b0e0-5d7c-ba19-d88de862ad90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6937de14-2dcc-5474-8d7e-c5f91fb0574f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['f11de56c-83c2-509d-8d13-4966c0a84f68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2cab8bcd-e3e2-5b6e-87ac-957239cf2b90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e52b77a9-4cb6-5fef-af5a-1fb74e535e3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['baf71877-bdd1-5a51-932c-ea31959c69ca', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['cb33e472-26d3-5149-8ca1-2b1218c5c31b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['22241703-06ed-5c36-a6fc-4f16f183620b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['1557f2bc-b966-526c-86c9-4fbee1673216', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['f6845d6d-32cc-5e48-950b-a2efb5bb76db', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['084c7c78-ac7a-5cb2-8307-dd942e9cd182', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['d7051af7-76a0-5bf9-8400-b10751bccf68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['4fd06ce5-42bf-522f-8fcc-8eabcce71cea', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['6aeabdb2-ae7c-5f4c-8084-53f8a1f439ac', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['2b86b372-c022-50ab-88d9-972cbaff3f20', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['10a68846-4ac9-59cc-a7bc-0788ddd03d30', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['c96141b1-b8c4-59fb-af26-5456e9fd0b42', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['449c6899-31a7-519a-8457-d268af25043a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['f1785909-382a-5e02-8dde-ea38e6b0843a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['56c9a226-5136-5a14-8948-47aa7b60182e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['29a19ae2-db0b-53e2-8a57-136850f3ac52', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['5d892867-dbff-551b-8ada-59265af845a8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5e54fb27-0e91-516c-9afd-c497eb96e45b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['01022853-10d1-5fe0-b6e7-05a02550d458', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['75467af3-5fe1-5e9f-b61c-687bc1f10aa2', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3875649e-f11b-559f-b059-04a2b0ee087a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['90ac98da-ede6-524a-810b-98386352229e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['14a7a77b-f7c5-5dfa-9675-d5d4bb667784', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['eee87161-3edc-530f-baba-ad74872676f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK,', ' Acute Myeloid Leukemia'], ['08b0c502-82be-5e1d-80d6-e6686e97ccda', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['ed961ae2-c10b-528d-9d0f-55f37a52e778', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['ce12c206-947d-5653-974b-d4191b4649db', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['4eeebc62-194e-5fb3-bc14-ad8e21ba09ce', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['53feb50a-6a0f-599a-a954-309fbe9a0de9', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['a7a4a697-71d5-54c5-95e7-85092d33c719', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['e36e66ab-7a85-5362-bbeb-4cf163baacb3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['bfebf10b-d14b-549b-a038-d12227a0698e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['8ab4d815-2021-5168-9698-9562844d44f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03574402', 'Phase II Umbrella Study Directed by Next Generation Sequencing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03574402', ' Phase 2', ' BCL2L11, BCL2L11 Deletion,', ' Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma'], ['3c4e65b7-ec15-5774-95d5-49e9e37661fe', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['b7b55cf4-1a82-58c2-92a0-9b9c171b6d84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['aceef024-5e37-51c3-9933-c07d372fff13', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['283939cc-045c-583b-8586-c76358cdff5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['36ed3b2a-14bf-5c6a-99eb-4b4891340959', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia'], ['32413726-a315-5b7a-9b0c-d0b7e4efe582', 'https://www.mycancergenome.org/content/clinical_trials/NCT03466320', 'DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03466320', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['9df9fe36-0475-5beb-bb1b-ea38618261b4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03455517', 'Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03455517', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['6b105b72-f072-51af-a694-bca48a81fc74', 'https://www.mycancergenome.org/content/clinical_trials/NCT03454984', 'SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03454984', ' Phase 2', ' Complex karyotype, MECOM,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['45176428-ba01-57ec-93bf-a627b91c9d44', 'https://www.mycancergenome.org/content/clinical_trials/NCT03439371', 'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03439371', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), RB1 Mutation AND TP53 Mutation, ELN Adverse Risk Group"
c4073622-6381-5451-bfc5-0dc4d8f52685,https://www.mycancergenome.org/content/alteration/tp53-nonsense/,TP53 Nonsense," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['447f5fc0-9755-5554-9489-52bf792f5e5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift,', ' Myelodysplastic Syndromes'], ['aed89f36-2dff-5e7a-9f3b-9694d21ff13c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['6c53b51c-ec0b-5963-be34-724106c30d40', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9b7526ff-6ce4-5147-972b-15c1d50cd667', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['7175024c-3075-5e83-ac67-913a6cef02da', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy,', ' Multiple Myeloma'], ['f8f4db5c-b2b4-5bc8-b49a-ed430280f5ad', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['48f6a3a9-0168-55ba-bdab-650edb0c22c1', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['76893720-4f00-56f2-a36d-96319e39d6e3', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['0730948e-03fe-5b5a-b69c-b52ad0d99b62', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['693e3850-fbbb-5b63-bd6a-a160f9c427d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['0336585b-cdc2-5db7-b929-4e2de4341cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['a572b921-9c3e-5c8d-9334-28ce340d7721', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['f769fae4-c2db-56b1-8f68-2078597fcdf7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['72abd7ae-4680-5b64-a09b-380d5bd6bd2c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['dfa8f137-1a3b-568d-b0a3-092e25ba1e85', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
269b555a-95a5-5802-b6bb-c0a8c811507d,https://www.mycancergenome.org/content/alteration/tp53-c-1-c-137-missense/,TP53 c.1-c.137 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['c27e1b05-4b8a-5f12-b857-e86effb7b653', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift,', ' Myelodysplastic Syndromes'], ['1e4d65ff-ce6b-5d92-9939-554bfb2e005a', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c8bc5be2-ea2d-576e-84b4-6aa027f56c49', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
3c6b1ac9-059f-5f3d-88bd-06d37472dd11,https://www.mycancergenome.org/content/alteration/tp53-c-142-c-212-missense/,TP53 c.142-c.212 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['659fd00d-ad10-56e6-b893-43e8f47719b7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift,', ' Myelodysplastic Syndromes'], ['7ea0ac07-9f00-59fb-895a-094e1d5c2c27', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c9a756fc-ae49-567a-be17-8988dd44867c', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
7407edb4-03c5-5b25-ba9b-8742d62bc94e,https://www.mycancergenome.org/content/alteration/tp53-c-217-c-1178-missense/,TP53 c.217-c.1178 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['0629feba-d546-551e-b654-26f8bf9bfb92', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift,', ' Myelodysplastic Syndromes'], ['a81fed8c-56f7-5f85-a75c-fa670584a139', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['7bc76597-92a2-5f63-a41d-9c48908cbb7e', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
eb6b3698-fb12-5db0-94a0-2b65a7a1096f,https://www.mycancergenome.org/content/alteration/tp53-frameshift/,TP53 Frameshift," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['773b840d-a0bf-54fa-8055-a2d50fd402d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift,', ' Myelodysplastic Syndromes'], ['74e18afb-e0b6-5215-ba31-65ed711ed2f4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['e8ec27f2-cfb1-589b-b983-0b6963e9b98c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9a68f134-c3ed-58de-8d6e-d7faf3634ae7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['91d83c6b-d3b5-5180-adbf-f152b0873091', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy,', ' Multiple Myeloma'], ['bdc5b528-c2bc-5ea1-a27a-cc6a20456106', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['7a3433d3-8a60-5ae6-bf27-caeb622041e9', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['f48415b8-7785-5024-8dc2-85513f4246a7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['75e44dd3-0602-570f-ab4d-ae1c844171ec', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4f4946c7-fa0e-59d2-a0b9-e39cce7a1c30', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['2a2e1ee8-7914-51be-9c9b-d2cfee7eb3c8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['09b9b4fb-7857-5fb3-b894-07c79a60c625', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['05d7ba44-424c-58f0-982e-3e6916ccfe2f', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['028ae3ba-5023-51d4-9dd3-1f96ca814984', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['517b5a62-0025-58b4-a78d-dfd21f9c36cf', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
c07a00ba-8a73-55f4-9c19-2fa957a8d589,https://www.mycancergenome.org/content/alteration/del-17-p13/,del(17)(p13)," Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 8, 3,"[['6fd5916f-f91a-55db-846a-b2245ff3ac60', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['65deaa23-b44d-5d89-8cbf-6a648e1dc914', 'https://www.mycancergenome.org/content/clinical_trials/NCT03943342', 'Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03943342', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia'], ['d293694e-f99f-573b-b2db-e4b36f2a4842', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['b4c0208e-2e42-5ba3-8ba1-f30f644087c7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03683277', 'IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03683277', ' Phase 2', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Multiple Myeloma'], ['a5d10f7a-517f-599c-bcb9-e2f5b8507ef7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03625388', 'Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03625388', ' Phase 2', ' ABL1, BCR, BCR-ABL1 Fusion,', ' Chronic Myeloid Leukemia'], ['616c00cc-7fcb-5879-8d95-0269a4730a9b', 'https://www.mycancergenome.org/content/clinical_trials/NCT02518555', 'Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02518555', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['5e60ba9f-207f-5696-8efa-14fdd2c1991d', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia']]"," 17p deletion group, del(11q), del(17p), or TP53 Missense Mutations"
edbc8f44-837f-5e73-9dae-161f44017d50,https://www.mycancergenome.org/content/alteration/tp53-codon-175-missense/,TP53 Codon 175 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['584f0cb2-196d-50cf-8571-5183f415f224', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'edbc8f44-837f-5e73-9dae-161f44017d50', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0dfd0073-1d59-5dce-b737-26b8fcdbe9ea,https://www.mycancergenome.org/content/alteration/tp53-codon-245-missense/,TP53 Codon 245 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['dc34c37f-0367-5489-9b23-cb1d28661739', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0dfd0073-1d59-5dce-b737-26b8fcdbe9ea', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
5aef6155-30cc-59d4-a900-af7b056d3c3e,https://www.mycancergenome.org/content/alteration/tp53-codon-248-missense/,TP53 Codon 248 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['0afacc31-c762-5ebb-bb29-30664eb6fbc5', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '5aef6155-30cc-59d4-a900-af7b056d3c3e', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
6ff8e186-58ca-5ded-98cd-228789184f15,https://www.mycancergenome.org/content/alteration/tp53-codon-273-missense/,TP53 Codon 273 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['f87e24bd-f06e-5fa0-bdb8-24b838509e84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '6ff8e186-58ca-5ded-98cd-228789184f15', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0ac59bdc-e47b-5e50-b8c2-856d5a528bd8,https://www.mycancergenome.org/content/alteration/tp53-codon-282-missense/,TP53 Codon 282 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['8e886948-d266-5c63-926a-8c04ab73b6af', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0ac59bdc-e47b-5e50-b8c2-856d5a528bd8', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
9fe84676-1bef-5cdc-95c3-c33f9658209f,https://www.mycancergenome.org/content/alteration/tp53-k132e/,TP53 K132E," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['148b646c-d6b4-59c7-a3e9-efbf1ac76504', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '9fe84676-1bef-5cdc-95c3-c33f9658209f', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
f60c488b-723e-5350-9c5b-d446d1f06e17,https://www.mycancergenome.org/content/alteration/tp53-k132n/,TP53 K132N," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['6dfa7e28-f1fc-5a15-aee9-7edfa1184520', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'f60c488b-723e-5350-9c5b-d446d1f06e17', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
6c2f74c4-62ff-5a6f-9bee-12723a40c35c,https://www.mycancergenome.org/content/alteration/tp53-mutation-germline/,TP53 Mutation (germline)," Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 8, 0,"[['e19c8958-eb02-52ca-bab7-53f3124d8153', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['e0f0c0f4-1363-53e8-899f-3e2d79718c6e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['c7a91999-5725-55bd-83d1-7c209364e848', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['5c3cfa58-e935-5fc1-a630-258099566f11', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['29323168-40ca-5422-ab24-b1061b7229f8', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss,', ' Medulloblastoma'], ['eca0ca48-eac3-527d-8f54-a1729ec5c75c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['f96380a3-fd32-5ebf-868d-5596fae3254c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['519bcf36-7c4d-5c6c-bf85-b245f1d57ced', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, SHH-Activated"
11717967-8881-51cf-a961-88598085ee04,https://www.mycancergenome.org/content/alteration/tp53-mutation-somatic/,TP53 Mutation (somatic)," Desmoplastic/Nodular Medulloblastoma, Gastric Adenocarcinoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 11, 0,"[['3b63dd08-f5ba-58b4-8b8d-f85a8d7e528f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['022e5e3a-262c-5e1c-843f-15f420b2624b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', '11717967-8881-51cf-a961-88598085ee04', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['c9ca4d40-cff8-5c8b-b27e-9a666a82f338', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['7fd24b12-032f-51e0-a186-6362520513b2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['32cc1a7a-4e80-591e-9047-3c483dea866b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['c9ab85ca-9b50-56bb-be65-7d5229f9c9fc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '11717967-8881-51cf-a961-88598085ee04', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss,', ' Medulloblastoma'], ['4f7f8a46-7499-583b-b7b9-813aae4d42fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '11717967-8881-51cf-a961-88598085ee04', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['7400aefa-8a50-5e85-9e3d-1e8a61c86384', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['6018fcaf-b49b-51c5-b441-4e8bd9bc9711', 'https://www.mycancergenome.org/content/clinical_trials/NCT02724579', 'Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT02724579', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma, Medulloblastoma, WNT-Activated'], ['3b6b479e-8f1e-58b2-9e19-d7d538412042', 'https://www.mycancergenome.org/content/clinical_trials/NCT02013154', 'A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab', '11717967-8881-51cf-a961-88598085ee04', ' NCT02013154', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma'], ['dc079969-9043-5f4d-af91-57931a18eb8f', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, WNT-Activated, Medulloblastoma, SHH-Activated"
20e3d8de-fee4-5710-9a2f-145210efff46,https://www.mycancergenome.org/content/alteration/tp53-r213l/,TP53 R213L," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['92888025-0cce-5e87-82f6-67004081fea6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '20e3d8de-fee4-5710-9a2f-145210efff46', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
72131208-da0f-5c55-99a3-c88e15ed0a71,https://www.mycancergenome.org/content/alteration/tp53-r249m/,TP53 R249M," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['43092bc5-b3db-5ce5-ab96-f302057e397d', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '72131208-da0f-5c55-99a3-c88e15ed0a71', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
bc65d8c8-e567-5949-af0f-81f840377a28,https://www.mycancergenome.org/content/alteration/tp53-s127y/,TP53 S127Y," Non-Small Cell Lung Carcinoma, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Malignant Solid Tumor, Lung Adenocarcinoma",, 1, 0,"[['5518a982-5ff1-509e-96f7-6d17bdc3a55f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'bc65d8c8-e567-5949-af0f-81f840377a28', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
854b04ef-860e-5032-b50c-b5a060ed67ae,https://www.mycancergenome.org/content/alteration/tp53-y220c/,TP53 Y220C," Malignant Breast Neoplasm, Non-Small Cell Lung Carcinoma, Malignant Ovarian Neoplasm, Hepatocellular Carcinoma, Squamous Cell Lung Carcinoma, Breast Ductal Carcinoma, Malignant Solid Tumor",, 1, 0,"[['62ffef8e-2268-5b72-a675-c67edb7e3044', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', '854b04ef-860e-5032-b50c-b5a060ed67ae', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor']]", None
7dee88b4-961c-53a3-b563-e2846809c859,https://www.mycancergenome.org/content/alteration/tp53-a119g/,TP53 A119G, None,,,,, None
20136a06-08ff-5b24-b177-42291df5b683,https://www.mycancergenome.org/content/alteration/tp53-a138p/,TP53 A138P, None,,,,, None
6ad6a957-ce71-59e3-b9c6-b8a6db9d5c4e,https://www.mycancergenome.org/content/alteration/tp53-a138v/,TP53 A138V, None,,,,, None
04059791-188f-5507-a141-41756021cb9e,https://www.mycancergenome.org/content/alteration/tp53-a159d/,TP53 A159D, None,,,,, None
8127c4d0-4f76-52a3-8c0f-482ac205712d,https://www.mycancergenome.org/content/alteration/tp53-a159p/,TP53 A159P, None,,,,, None
ec85f991-429a-55c0-9ade-fc7c5d2b93f4,https://www.mycancergenome.org/content/alteration/tp53-a159v/,TP53 A159V, None,,,,, None
cfbd00b2-3cc2-5ab1-a645-e64d44f68dcf,https://www.mycancergenome.org/content/alteration/tp53-a161d/,TP53 A161D, None,,,,, None
7af531a2-228f-566d-b2b7-aa9333a600c2,https://www.mycancergenome.org/content/alteration/tp53-a161s/,TP53 A161S, None,,,,, None
,Link,Biomarkers,Diseases,Pathways,Clinical_Trials,Drugs,ClinicalTrialsTitle,Alteration_Groups
c76e588f-080a-5f4e-a338-955130da287d,https://www.mycancergenome.org/content/gene/tp53/,TP53," Cancer, Vaginal Carcinoma, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Neuroblastoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Transitional Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Large Cell Lung Carcinoma, Clear Cell Renal Cell Carcinoma, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Acute Lymphoblastic Leukemia, Vulvar Carcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Hepatocellular Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Pancreatic Ductal Adenocarcinoma, Lymphoma, Malignant Peritoneal Neoplasm, Malignant Bladder Neoplasm, Benign Fibrous Histiocytoma, Malignant Head and Neck Neoplasm, Acute Myeloid Leukemia, Malignant Solid Tumor, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Breast Ductal Carcinoma, Anal Carcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Fallopian Tube Neoplasm, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Colon Neuroendocrine Neoplasm, Histiocytic And Dendritic Cell Cancer, Urothelial Carcinoma, Malignant Ovarian Epithelial Tumor", Cell cycle control, 206, 3,"[['8920c079-a6c0-5fa5-b5f0-aadce7ec0867', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['559d2f86-2a79-5e97-8b86-cbf90fa17ba6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['b0b04d8b-edba-56eb-9e00-1b5a069e185c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['c927ab37-1d1d-5755-a154-c18253fd367c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['686de7ed-a069-5fbb-9d0b-849398d393d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['97d2d07b-8fb4-55a5-8fae-682c4a5a091b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['1d8ef049-8e73-57c1-a414-127323b655d8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['edeb4236-f82c-56ac-b5bb-a7b247a407d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['81d544bf-76fa-5126-8bc4-ae12ff849510', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['2891c7b5-4548-5bc3-8cc1-ce2024027b6c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['428ca4a8-a020-51fe-8ed8-d1ee814d4a6f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor'], ['ef049a6e-21af-54d6-b69f-cfc4ab9b484c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['f876db17-7031-590a-80b8-f05f6b93cc07', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['3c6ec96c-d51b-53d2-b5e7-abd3106c6254', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['d0a1923a-945e-5758-bad0-7d964e2242f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['47faa36b-f117-52a2-a0c7-4a748fa30bfa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['0634f789-b86b-571a-922b-51d066058198', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['37ae8aef-3ce7-5a6a-8f0d-37c04d0c9b32', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['f435a5bb-177c-5d46-b831-b10d177b9d8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['bc6695f6-352a-5dd5-94b6-5b9dc00fd71a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2efa4aac-8164-5bff-a495-6626467a2375', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['8104b769-6031-50d3-b783-7379c93cd6c0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['7ac4e91c-40fa-5342-b988-2af33f945e67', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['77e2ffd3-7719-58e6-a1f5-3759cf00b74e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['aa95ff76-4526-5f44-8e9a-61d09c518749', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['555105c4-6ee2-5266-904d-244146ba85dd', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['1e6a42d4-1d17-5c82-8efd-a17d01604406', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a26b4e11-e0b1-5036-978d-8465070587cb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3da6e26f-c7ec-5113-805b-80b7302eae6b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['f1e66d04-9749-5f61-97d1-424ae2704448', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['8290b969-52fd-5ab6-a2a3-1dd845c68233', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a27cb61-7185-5eaa-b87b-ae2ba0387fa6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['ae756cad-e710-556d-b5ef-5e22ca23ae04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d0a5d9a6-03a3-5abd-a01f-92a1e71e0984', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['cfe127b9-93ba-5b83-986a-5a2a6ecca130', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['ddc6a312-3031-53c5-965e-94ac74f8b6aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['403dc844-4a13-5dc9-8d44-8bc4aaa0ffb1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['0adf2c15-fc9b-5c1e-8a0d-2b60253f9b4d', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['cf8e4c89-da0d-5e84-97dd-c0f4646a4166', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['526098fa-0c19-5bac-b9ec-1d29111862ab', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e51fc27a-baaa-58b8-8df6-6c5b2f8d984c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['4d3e8616-9c78-5e7c-a1cd-393769c71c90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['df545b25-510a-5a03-882f-6026d5665f0b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['9b29392c-b012-51ea-88bc-4a024dfc2c07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma'], ['f94ad441-3d98-53ac-a220-858c6ea23745', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c3c0333f-9623-53d2-bd07-3558d3ad0247', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['d7166f7a-728e-5550-82f1-b6c76863f2aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6e6afa2f-0af9-5d89-80fe-3442ce365909', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['b37fb9cc-bf33-5e4a-8c7f-1284f96e0926', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['f25dfe3b-b863-5ca3-96e0-a07dc5aa7dd4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['7c6bd3fa-b534-5f32-913c-13efe09a988c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['46d8d3b9-c1ba-505c-8c0b-277178274475', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['23ba20e7-a04f-5f1e-b7c3-05a463a80d4c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['5395e287-c588-5e7d-9705-05cf7638f0be', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['2857f779-7074-5887-9fb5-17ee5d67ea79', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['8476f372-4407-577a-a1e5-10066857162e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['ed558021-a193-5cd4-a0f1-2dfec163d38e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma'], ['12d2c9ee-8d91-574a-97ee-8c3ac141e289', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['7d56363c-3ca4-5237-a7c7-cb9d80ae5608', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['4b4e37a4-3dcb-5af1-9205-88e209220850', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts']]",
eba36364-821f-5f60-b93e-4857edc625ee,https://www.mycancergenome.org/content/alteration/tp53-loss/,TP53 Loss," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Ovarian Serous Tumor, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Malignant Bladder Neoplasm, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 187, 0,"[['e221663b-5a35-5781-bbd3-acada7f46f8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['75cd3142-59f8-5caf-adab-dad872fbc7f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['7c32e385-22e4-5688-819c-4219039fda73', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['507a6b75-20dd-5e8d-abb2-b8196882db5c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['762c33e0-037f-553d-b2b4-c73d4af3b9d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['ca08e81b-64ec-5e41-b861-3d109aaed50a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4b2e40ed-67de-5c6c-9834-d80205751186', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['1f4561b8-5862-59fe-a960-ee52834e42c3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['c64afea7-5389-5d3a-98f7-0d22257d5bad', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['58779054-877f-5d9e-a552-42ecde884ed0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['35a2a8e4-de0f-59af-b5dd-f26637c7c010', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6b268729-eb67-5362-bb67-d48a43d0e20e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a4621e3f-3a6e-51bd-9cd6-117a397a7a03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['19f47721-6769-514d-9ce5-a8647c3c7258', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['69481b88-9661-5764-9f6e-ff06e1afbca5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['2636aeed-9b11-55de-888e-4840f09a44df', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['2e51066e-ca32-5524-83a2-0f6ff1cd1cd6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['82575ecc-4aeb-5cdb-b9ce-aac82265f105', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['c0c1e6c1-eac2-5830-a7f1-2af3091f8b99', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5ef759a2-1f77-5835-a0a4-a9bd3ae96f03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['9063a22a-c9e8-5ed5-a226-f08e49d1be47', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['6fbe5e54-7397-5c5a-afa2-b5f980f4d677', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['30396263-e633-5e5b-b2f9-e36d15940e39', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c53a462b-1d08-54f5-bb73-df53c3f7caf5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['62d5ae16-1908-5a7d-93c4-adf601d0148f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a2d4906-7ff2-52da-aa03-879b446eb5d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a3c95bdb-87df-5825-bcf4-3d547ca4a9b1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['5a92b405-dcbc-5857-bd97-16d00864c6fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['d6153efa-d93e-5939-9290-a4fddd864cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['4153cbc8-adb3-556b-a0ea-195e9a842928', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['6c369150-0ca4-5ea1-8c34-0efaea36c614', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d8777ca4-4beb-59d6-97df-02633de11587', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['1e8bd600-5a56-54a2-9f95-861a142ea82f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['510aaf02-415b-58c8-b95b-a6ed6e122e68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4c8949f0-9984-5c33-a764-737c02d3d529', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['24ba6965-b932-5e56-a39d-7c688648f3d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f7b4e5ac-0098-50ef-a807-85c14ad681c2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['92f18279-c687-5cc4-b720-47734b22ae3f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f4aa0065-93a7-582f-b025-98d3908c5a94', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['f5ffe9a2-2a95-5e84-8469-51090a0449a1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['f001c121-0641-5df9-81ce-a209ccbdcb07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['251b9e77-7989-55ff-b71a-12c3a0c97083', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3e54bc33-a75f-50a6-9a3f-699b9c7f6685', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4caa5049-8cfd-5822-95dd-80adf34b8341', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6ceb47fd-d396-5eca-b527-ea6c61e2119b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['c63b1222-783c-578f-bf08-2290574e900b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['179a8789-afeb-5502-a57a-770cbf30db55', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['81bff8b8-6fac-5a5c-8e81-27395eea14bc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['885d536c-f17f-5837-b8fa-ce13bcc4992f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['4d1b46b7-1239-5840-b608-4590bfc2178e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['d373e6e1-5bd3-5f83-8b42-799026988bf1', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['f596dded-3c13-54d2-afcc-5940bfac2c69', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['46854f60-ad43-51de-9af3-25d368ee1488', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['020c7ed4-e01c-543b-b728-62c2768fdb51', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['2c32d193-1165-5ad8-9dbb-303619d8a194', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['a67abb46-6efa-5c25-978c-90b72f708423', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['583c481f-5151-5f2c-af2c-82a6fb53c0d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['21d7eab8-2c4d-5418-976f-4f2a2c800b1b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['316a53ff-e67c-57e5-a376-357b288d5bb7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['0d2eeb41-053d-5aa6-b0ac-a82c1e023a3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), ELN Adverse Risk Group, Medulloblastoma, SHH-Activated"
0abac394-06e2-5d38-8845-8aca7485d7b5,https://www.mycancergenome.org/content/alteration/tp53-mutation/,TP53 Mutation," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Myeloid Sarcoma, Neuroblastoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Benign Fibrous Histiocytoma, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Colorectal Neoplasm, Gastric Carcinoma, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 175, 0,"[['f7b78afe-1dc1-544b-86ca-fc303608fe12', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['3a06b6c1-b916-585e-a8ee-bf0d44603555', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['d401d6ac-02de-5e98-9416-db7a5d609cae', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['11bbc0c7-e808-5c5b-b9a4-34854b768042', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['ecfb2c62-17f7-5a23-b492-04243f363a68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['50a3a24a-ffba-56d3-b0f4-dd00e66878f5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['144034da-587c-5a5c-91b8-88ba48987da8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['16bf36af-4f2b-51ae-a6b8-b1a112e0d541', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['92dbd658-5154-5f7c-bdac-452374dadf04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['4c48bf2b-8585-59aa-84c1-fed10995262c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['41d02d3c-8e93-5775-bc6d-2ba1db0df6b0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a9a7590f-c952-5fa5-899a-8d504e6636a6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['a778f5c1-738a-5249-b3e5-e2dfc385fc21', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['bceb75d4-b0e0-5d7c-ba19-d88de862ad90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6937de14-2dcc-5474-8d7e-c5f91fb0574f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['f11de56c-83c2-509d-8d13-4966c0a84f68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2cab8bcd-e3e2-5b6e-87ac-957239cf2b90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e52b77a9-4cb6-5fef-af5a-1fb74e535e3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['baf71877-bdd1-5a51-932c-ea31959c69ca', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['cb33e472-26d3-5149-8ca1-2b1218c5c31b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['22241703-06ed-5c36-a6fc-4f16f183620b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['1557f2bc-b966-526c-86c9-4fbee1673216', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['f6845d6d-32cc-5e48-950b-a2efb5bb76db', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['084c7c78-ac7a-5cb2-8307-dd942e9cd182', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['d7051af7-76a0-5bf9-8400-b10751bccf68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['4fd06ce5-42bf-522f-8fcc-8eabcce71cea', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['6aeabdb2-ae7c-5f4c-8084-53f8a1f439ac', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['2b86b372-c022-50ab-88d9-972cbaff3f20', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['10a68846-4ac9-59cc-a7bc-0788ddd03d30', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['c96141b1-b8c4-59fb-af26-5456e9fd0b42', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['449c6899-31a7-519a-8457-d268af25043a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['f1785909-382a-5e02-8dde-ea38e6b0843a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['56c9a226-5136-5a14-8948-47aa7b60182e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['29a19ae2-db0b-53e2-8a57-136850f3ac52', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['5d892867-dbff-551b-8ada-59265af845a8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5e54fb27-0e91-516c-9afd-c497eb96e45b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['01022853-10d1-5fe0-b6e7-05a02550d458', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['75467af3-5fe1-5e9f-b61c-687bc1f10aa2', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3875649e-f11b-559f-b059-04a2b0ee087a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['90ac98da-ede6-524a-810b-98386352229e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['14a7a77b-f7c5-5dfa-9675-d5d4bb667784', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['eee87161-3edc-530f-baba-ad74872676f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['08b0c502-82be-5e1d-80d6-e6686e97ccda', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['ed961ae2-c10b-528d-9d0f-55f37a52e778', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['ce12c206-947d-5653-974b-d4191b4649db', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['4eeebc62-194e-5fb3-bc14-ad8e21ba09ce', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['53feb50a-6a0f-599a-a954-309fbe9a0de9', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['a7a4a697-71d5-54c5-95e7-85092d33c719', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['e36e66ab-7a85-5362-bbeb-4cf163baacb3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['bfebf10b-d14b-549b-a038-d12227a0698e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['8ab4d815-2021-5168-9698-9562844d44f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03574402', 'Phase II Umbrella Study Directed by Next Generation Sequencing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03574402', ' Phase 2', ' BCL2L11, BCL2L11 Deletion,', ' Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma'], ['3c4e65b7-ec15-5774-95d5-49e9e37661fe', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['b7b55cf4-1a82-58c2-92a0-9b9c171b6d84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['aceef024-5e37-51c3-9933-c07d372fff13', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['283939cc-045c-583b-8586-c76358cdff5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['36ed3b2a-14bf-5c6a-99eb-4b4891340959', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia'], ['32413726-a315-5b7a-9b0c-d0b7e4efe582', 'https://www.mycancergenome.org/content/clinical_trials/NCT03466320', 'DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03466320', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['9df9fe36-0475-5beb-bb1b-ea38618261b4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03455517', 'Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03455517', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['6b105b72-f072-51af-a694-bca48a81fc74', 'https://www.mycancergenome.org/content/clinical_trials/NCT03454984', 'SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03454984', ' Phase 2', ' Complex karyotype, MECOM,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['45176428-ba01-57ec-93bf-a627b91c9d44', 'https://www.mycancergenome.org/content/clinical_trials/NCT03439371', 'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03439371', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), RB1 Mutation AND TP53 Mutation, ELN Adverse Risk Group"
c4073622-6381-5451-bfc5-0dc4d8f52685,https://www.mycancergenome.org/content/alteration/tp53-nonsense/,TP53 Nonsense," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['447f5fc0-9755-5554-9489-52bf792f5e5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['aed89f36-2dff-5e7a-9f3b-9694d21ff13c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['6c53b51c-ec0b-5963-be34-724106c30d40', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9b7526ff-6ce4-5147-972b-15c1d50cd667', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['7175024c-3075-5e83-ac67-913a6cef02da', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['f8f4db5c-b2b4-5bc8-b49a-ed430280f5ad', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['48f6a3a9-0168-55ba-bdab-650edb0c22c1', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['76893720-4f00-56f2-a36d-96319e39d6e3', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['0730948e-03fe-5b5a-b69c-b52ad0d99b62', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['693e3850-fbbb-5b63-bd6a-a160f9c427d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['0336585b-cdc2-5db7-b929-4e2de4341cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['a572b921-9c3e-5c8d-9334-28ce340d7721', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['f769fae4-c2db-56b1-8f68-2078597fcdf7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['72abd7ae-4680-5b64-a09b-380d5bd6bd2c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['dfa8f137-1a3b-568d-b0a3-092e25ba1e85', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
269b555a-95a5-5802-b6bb-c0a8c811507d,https://www.mycancergenome.org/content/alteration/tp53-c-1-c-137-missense/,TP53 c.1-c.137 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['c27e1b05-4b8a-5f12-b857-e86effb7b653', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['1e4d65ff-ce6b-5d92-9939-554bfb2e005a', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c8bc5be2-ea2d-576e-84b4-6aa027f56c49', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
3c6b1ac9-059f-5f3d-88bd-06d37472dd11,https://www.mycancergenome.org/content/alteration/tp53-c-142-c-212-missense/,TP53 c.142-c.212 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['659fd00d-ad10-56e6-b893-43e8f47719b7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['7ea0ac07-9f00-59fb-895a-094e1d5c2c27', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c9a756fc-ae49-567a-be17-8988dd44867c', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
7407edb4-03c5-5b25-ba9b-8742d62bc94e,https://www.mycancergenome.org/content/alteration/tp53-c-217-c-1178-missense/,TP53 c.217-c.1178 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['0629feba-d546-551e-b654-26f8bf9bfb92', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['a81fed8c-56f7-5f85-a75c-fa670584a139', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['7bc76597-92a2-5f63-a41d-9c48908cbb7e', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
eb6b3698-fb12-5db0-94a0-2b65a7a1096f,https://www.mycancergenome.org/content/alteration/tp53-frameshift/,TP53 Frameshift," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['773b840d-a0bf-54fa-8055-a2d50fd402d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['74e18afb-e0b6-5215-ba31-65ed711ed2f4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['e8ec27f2-cfb1-589b-b983-0b6963e9b98c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9a68f134-c3ed-58de-8d6e-d7faf3634ae7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['91d83c6b-d3b5-5180-adbf-f152b0873091', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['bdc5b528-c2bc-5ea1-a27a-cc6a20456106', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['7a3433d3-8a60-5ae6-bf27-caeb622041e9', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['f48415b8-7785-5024-8dc2-85513f4246a7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['75e44dd3-0602-570f-ab4d-ae1c844171ec', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4f4946c7-fa0e-59d2-a0b9-e39cce7a1c30', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['2a2e1ee8-7914-51be-9c9b-d2cfee7eb3c8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['09b9b4fb-7857-5fb3-b894-07c79a60c625', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['05d7ba44-424c-58f0-982e-3e6916ccfe2f', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['028ae3ba-5023-51d4-9dd3-1f96ca814984', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['517b5a62-0025-58b4-a78d-dfd21f9c36cf', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
c07a00ba-8a73-55f4-9c19-2fa957a8d589,https://www.mycancergenome.org/content/alteration/del-17-p13/,del(17)(p13)," Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 8, 3,"[['6fd5916f-f91a-55db-846a-b2245ff3ac60', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['65deaa23-b44d-5d89-8cbf-6a648e1dc914', 'https://www.mycancergenome.org/content/clinical_trials/NCT03943342', 'Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03943342', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia'], ['d293694e-f99f-573b-b2db-e4b36f2a4842', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['b4c0208e-2e42-5ba3-8ba1-f30f644087c7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03683277', 'IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03683277', ' Phase 2', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Multiple Myeloma'], ['a5d10f7a-517f-599c-bcb9-e2f5b8507ef7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03625388', 'Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03625388', ' Phase 2', ' ABL1, BCR, BCR-ABL1 Fusion,', ' Chronic Myeloid Leukemia'], ['616c00cc-7fcb-5879-8d95-0269a4730a9b', 'https://www.mycancergenome.org/content/clinical_trials/NCT02518555', 'Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02518555', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['5e60ba9f-207f-5696-8efa-14fdd2c1991d', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia']]"," 17p deletion group, del(11q), del(17p), or TP53 Missense Mutations"
edbc8f44-837f-5e73-9dae-161f44017d50,https://www.mycancergenome.org/content/alteration/tp53-codon-175-missense/,TP53 Codon 175 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['584f0cb2-196d-50cf-8571-5183f415f224', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'edbc8f44-837f-5e73-9dae-161f44017d50', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0dfd0073-1d59-5dce-b737-26b8fcdbe9ea,https://www.mycancergenome.org/content/alteration/tp53-codon-245-missense/,TP53 Codon 245 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['dc34c37f-0367-5489-9b23-cb1d28661739', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0dfd0073-1d59-5dce-b737-26b8fcdbe9ea', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
5aef6155-30cc-59d4-a900-af7b056d3c3e,https://www.mycancergenome.org/content/alteration/tp53-codon-248-missense/,TP53 Codon 248 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['0afacc31-c762-5ebb-bb29-30664eb6fbc5', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '5aef6155-30cc-59d4-a900-af7b056d3c3e', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
6ff8e186-58ca-5ded-98cd-228789184f15,https://www.mycancergenome.org/content/alteration/tp53-codon-273-missense/,TP53 Codon 273 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['f87e24bd-f06e-5fa0-bdb8-24b838509e84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '6ff8e186-58ca-5ded-98cd-228789184f15', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0ac59bdc-e47b-5e50-b8c2-856d5a528bd8,https://www.mycancergenome.org/content/alteration/tp53-codon-282-missense/,TP53 Codon 282 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['8e886948-d266-5c63-926a-8c04ab73b6af', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0ac59bdc-e47b-5e50-b8c2-856d5a528bd8', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
9fe84676-1bef-5cdc-95c3-c33f9658209f,https://www.mycancergenome.org/content/alteration/tp53-k132e/,TP53 K132E," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['148b646c-d6b4-59c7-a3e9-efbf1ac76504', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '9fe84676-1bef-5cdc-95c3-c33f9658209f', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
f60c488b-723e-5350-9c5b-d446d1f06e17,https://www.mycancergenome.org/content/alteration/tp53-k132n/,TP53 K132N," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['6dfa7e28-f1fc-5a15-aee9-7edfa1184520', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'f60c488b-723e-5350-9c5b-d446d1f06e17', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
6c2f74c4-62ff-5a6f-9bee-12723a40c35c,https://www.mycancergenome.org/content/alteration/tp53-mutation-germline/,TP53 Mutation (germline)," Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 8, 0,"[['e19c8958-eb02-52ca-bab7-53f3124d8153', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['e0f0c0f4-1363-53e8-899f-3e2d79718c6e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['c7a91999-5725-55bd-83d1-7c209364e848', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['5c3cfa58-e935-5fc1-a630-258099566f11', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['29323168-40ca-5422-ab24-b1061b7229f8', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['eca0ca48-eac3-527d-8f54-a1729ec5c75c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['f96380a3-fd32-5ebf-868d-5596fae3254c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['519bcf36-7c4d-5c6c-bf85-b245f1d57ced', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, SHH-Activated"
11717967-8881-51cf-a961-88598085ee04,https://www.mycancergenome.org/content/alteration/tp53-mutation-somatic/,TP53 Mutation (somatic)," Desmoplastic/Nodular Medulloblastoma, Gastric Adenocarcinoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 11, 0,"[['3b63dd08-f5ba-58b4-8b8d-f85a8d7e528f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['022e5e3a-262c-5e1c-843f-15f420b2624b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', '11717967-8881-51cf-a961-88598085ee04', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['c9ca4d40-cff8-5c8b-b27e-9a666a82f338', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['7fd24b12-032f-51e0-a186-6362520513b2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['32cc1a7a-4e80-591e-9047-3c483dea866b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['c9ab85ca-9b50-56bb-be65-7d5229f9c9fc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '11717967-8881-51cf-a961-88598085ee04', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['4f7f8a46-7499-583b-b7b9-813aae4d42fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '11717967-8881-51cf-a961-88598085ee04', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['7400aefa-8a50-5e85-9e3d-1e8a61c86384', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['6018fcaf-b49b-51c5-b441-4e8bd9bc9711', 'https://www.mycancergenome.org/content/clinical_trials/NCT02724579', 'Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT02724579', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma, Medulloblastoma, WNT-Activated'], ['3b6b479e-8f1e-58b2-9e19-d7d538412042', 'https://www.mycancergenome.org/content/clinical_trials/NCT02013154', 'A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab', '11717967-8881-51cf-a961-88598085ee04', ' NCT02013154', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma'], ['dc079969-9043-5f4d-af91-57931a18eb8f', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, WNT-Activated, Medulloblastoma, SHH-Activated"
20e3d8de-fee4-5710-9a2f-145210efff46,https://www.mycancergenome.org/content/alteration/tp53-r213l/,TP53 R213L," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['92888025-0cce-5e87-82f6-67004081fea6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '20e3d8de-fee4-5710-9a2f-145210efff46', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
72131208-da0f-5c55-99a3-c88e15ed0a71,https://www.mycancergenome.org/content/alteration/tp53-r249m/,TP53 R249M," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['43092bc5-b3db-5ce5-ab96-f302057e397d', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '72131208-da0f-5c55-99a3-c88e15ed0a71', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
bc65d8c8-e567-5949-af0f-81f840377a28,https://www.mycancergenome.org/content/alteration/tp53-s127y/,TP53 S127Y," Non-Small Cell Lung Carcinoma, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Malignant Solid Tumor, Lung Adenocarcinoma",, 1, 0,"[['5518a982-5ff1-509e-96f7-6d17bdc3a55f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'bc65d8c8-e567-5949-af0f-81f840377a28', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
854b04ef-860e-5032-b50c-b5a060ed67ae,https://www.mycancergenome.org/content/alteration/tp53-y220c/,TP53 Y220C," Malignant Breast Neoplasm, Non-Small Cell Lung Carcinoma, Malignant Ovarian Neoplasm, Hepatocellular Carcinoma, Squamous Cell Lung Carcinoma, Breast Ductal Carcinoma, Malignant Solid Tumor",, 1, 0,"[['62ffef8e-2268-5b72-a675-c67edb7e3044', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', '854b04ef-860e-5032-b50c-b5a060ed67ae', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor']]", None
7dee88b4-961c-53a3-b563-e2846809c859,https://www.mycancergenome.org/content/alteration/tp53-a119g/,TP53 A119G, None,,,,, None
20136a06-08ff-5b24-b177-42291df5b683,https://www.mycancergenome.org/content/alteration/tp53-a138p/,TP53 A138P, None,,,,, None
6ad6a957-ce71-59e3-b9c6-b8a6db9d5c4e,https://www.mycancergenome.org/content/alteration/tp53-a138v/,TP53 A138V, None,,,,, None
04059791-188f-5507-a141-41756021cb9e,https://www.mycancergenome.org/content/alteration/tp53-a159d/,TP53 A159D, None,,,,, None
8127c4d0-4f76-52a3-8c0f-482ac205712d,https://www.mycancergenome.org/content/alteration/tp53-a159p/,TP53 A159P, None,,,,, None
ec85f991-429a-55c0-9ade-fc7c5d2b93f4,https://www.mycancergenome.org/content/alteration/tp53-a159v/,TP53 A159V, None,,,,, None
cfbd00b2-3cc2-5ab1-a645-e64d44f68dcf,https://www.mycancergenome.org/content/alteration/tp53-a161d/,TP53 A161D, None,,,,, None
7af531a2-228f-566d-b2b7-aa9333a600c2,https://www.mycancergenome.org/content/alteration/tp53-a161s/,TP53 A161S, None,,,,, None
,Link,Biomarkers,Diseases,Pathways,Clinical_Trials,Drugs,ClinicalTrialsTitle,Alteration_Groups
c76e588f-080a-5f4e-a338-955130da287d,https://www.mycancergenome.org/content/gene/tp53/,TP53," Cancer, Vaginal Carcinoma, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Neuroblastoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Transitional Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Large Cell Lung Carcinoma, Clear Cell Renal Cell Carcinoma, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Acute Lymphoblastic Leukemia, Vulvar Carcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Hepatocellular Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Pancreatic Ductal Adenocarcinoma, Lymphoma, Malignant Peritoneal Neoplasm, Malignant Bladder Neoplasm, Benign Fibrous Histiocytoma, Malignant Head and Neck Neoplasm, Acute Myeloid Leukemia, Malignant Solid Tumor, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Breast Ductal Carcinoma, Anal Carcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Fallopian Tube Neoplasm, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Colon Neuroendocrine Neoplasm, Histiocytic And Dendritic Cell Cancer, Urothelial Carcinoma, Malignant Ovarian Epithelial Tumor", Cell cycle control, 206, 3,"[['8920c079-a6c0-5fa5-b5f0-aadce7ec0867', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['559d2f86-2a79-5e97-8b86-cbf90fa17ba6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['b0b04d8b-edba-56eb-9e00-1b5a069e185c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['c927ab37-1d1d-5755-a154-c18253fd367c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['686de7ed-a069-5fbb-9d0b-849398d393d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['97d2d07b-8fb4-55a5-8fae-682c4a5a091b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['1d8ef049-8e73-57c1-a414-127323b655d8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['edeb4236-f82c-56ac-b5bb-a7b247a407d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['81d544bf-76fa-5126-8bc4-ae12ff849510', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['2891c7b5-4548-5bc3-8cc1-ce2024027b6c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['428ca4a8-a020-51fe-8ed8-d1ee814d4a6f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor'], ['ef049a6e-21af-54d6-b69f-cfc4ab9b484c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['f876db17-7031-590a-80b8-f05f6b93cc07', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['3c6ec96c-d51b-53d2-b5e7-abd3106c6254', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['d0a1923a-945e-5758-bad0-7d964e2242f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['47faa36b-f117-52a2-a0c7-4a748fa30bfa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['0634f789-b86b-571a-922b-51d066058198', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['37ae8aef-3ce7-5a6a-8f0d-37c04d0c9b32', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['f435a5bb-177c-5d46-b831-b10d177b9d8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['bc6695f6-352a-5dd5-94b6-5b9dc00fd71a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2efa4aac-8164-5bff-a495-6626467a2375', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['8104b769-6031-50d3-b783-7379c93cd6c0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['7ac4e91c-40fa-5342-b988-2af33f945e67', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['77e2ffd3-7719-58e6-a1f5-3759cf00b74e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['aa95ff76-4526-5f44-8e9a-61d09c518749', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['555105c4-6ee2-5266-904d-244146ba85dd', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['1e6a42d4-1d17-5c82-8efd-a17d01604406', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a26b4e11-e0b1-5036-978d-8465070587cb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3da6e26f-c7ec-5113-805b-80b7302eae6b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['f1e66d04-9749-5f61-97d1-424ae2704448', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['8290b969-52fd-5ab6-a2a3-1dd845c68233', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a27cb61-7185-5eaa-b87b-ae2ba0387fa6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['ae756cad-e710-556d-b5ef-5e22ca23ae04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d0a5d9a6-03a3-5abd-a01f-92a1e71e0984', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['cfe127b9-93ba-5b83-986a-5a2a6ecca130', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['ddc6a312-3031-53c5-965e-94ac74f8b6aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['403dc844-4a13-5dc9-8d44-8bc4aaa0ffb1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['0adf2c15-fc9b-5c1e-8a0d-2b60253f9b4d', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['cf8e4c89-da0d-5e84-97dd-c0f4646a4166', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['526098fa-0c19-5bac-b9ec-1d29111862ab', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e51fc27a-baaa-58b8-8df6-6c5b2f8d984c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['4d3e8616-9c78-5e7c-a1cd-393769c71c90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['df545b25-510a-5a03-882f-6026d5665f0b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['9b29392c-b012-51ea-88bc-4a024dfc2c07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma'], ['f94ad441-3d98-53ac-a220-858c6ea23745', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c3c0333f-9623-53d2-bd07-3558d3ad0247', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['d7166f7a-728e-5550-82f1-b6c76863f2aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6e6afa2f-0af9-5d89-80fe-3442ce365909', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['b37fb9cc-bf33-5e4a-8c7f-1284f96e0926', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['f25dfe3b-b863-5ca3-96e0-a07dc5aa7dd4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['7c6bd3fa-b534-5f32-913c-13efe09a988c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['46d8d3b9-c1ba-505c-8c0b-277178274475', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['23ba20e7-a04f-5f1e-b7c3-05a463a80d4c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['5395e287-c588-5e7d-9705-05cf7638f0be', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['2857f779-7074-5887-9fb5-17ee5d67ea79', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['8476f372-4407-577a-a1e5-10066857162e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['ed558021-a193-5cd4-a0f1-2dfec163d38e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma'], ['12d2c9ee-8d91-574a-97ee-8c3ac141e289', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['7d56363c-3ca4-5237-a7c7-cb9d80ae5608', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['4b4e37a4-3dcb-5af1-9205-88e209220850', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts']]",
eba36364-821f-5f60-b93e-4857edc625ee,https://www.mycancergenome.org/content/alteration/tp53-loss/,TP53 Loss," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Ovarian Serous Tumor, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Malignant Bladder Neoplasm, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 187, 0,"[['e221663b-5a35-5781-bbd3-acada7f46f8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['75cd3142-59f8-5caf-adab-dad872fbc7f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['7c32e385-22e4-5688-819c-4219039fda73', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['507a6b75-20dd-5e8d-abb2-b8196882db5c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['762c33e0-037f-553d-b2b4-c73d4af3b9d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['ca08e81b-64ec-5e41-b861-3d109aaed50a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4b2e40ed-67de-5c6c-9834-d80205751186', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['1f4561b8-5862-59fe-a960-ee52834e42c3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['c64afea7-5389-5d3a-98f7-0d22257d5bad', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['58779054-877f-5d9e-a552-42ecde884ed0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['35a2a8e4-de0f-59af-b5dd-f26637c7c010', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6b268729-eb67-5362-bb67-d48a43d0e20e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a4621e3f-3a6e-51bd-9cd6-117a397a7a03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['19f47721-6769-514d-9ce5-a8647c3c7258', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['69481b88-9661-5764-9f6e-ff06e1afbca5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['2636aeed-9b11-55de-888e-4840f09a44df', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['2e51066e-ca32-5524-83a2-0f6ff1cd1cd6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['82575ecc-4aeb-5cdb-b9ce-aac82265f105', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['c0c1e6c1-eac2-5830-a7f1-2af3091f8b99', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5ef759a2-1f77-5835-a0a4-a9bd3ae96f03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['9063a22a-c9e8-5ed5-a226-f08e49d1be47', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['6fbe5e54-7397-5c5a-afa2-b5f980f4d677', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['30396263-e633-5e5b-b2f9-e36d15940e39', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c53a462b-1d08-54f5-bb73-df53c3f7caf5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['62d5ae16-1908-5a7d-93c4-adf601d0148f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a2d4906-7ff2-52da-aa03-879b446eb5d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a3c95bdb-87df-5825-bcf4-3d547ca4a9b1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['5a92b405-dcbc-5857-bd97-16d00864c6fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['d6153efa-d93e-5939-9290-a4fddd864cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['4153cbc8-adb3-556b-a0ea-195e9a842928', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['6c369150-0ca4-5ea1-8c34-0efaea36c614', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d8777ca4-4beb-59d6-97df-02633de11587', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['1e8bd600-5a56-54a2-9f95-861a142ea82f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['510aaf02-415b-58c8-b95b-a6ed6e122e68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4c8949f0-9984-5c33-a764-737c02d3d529', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['24ba6965-b932-5e56-a39d-7c688648f3d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f7b4e5ac-0098-50ef-a807-85c14ad681c2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['92f18279-c687-5cc4-b720-47734b22ae3f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f4aa0065-93a7-582f-b025-98d3908c5a94', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['f5ffe9a2-2a95-5e84-8469-51090a0449a1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['f001c121-0641-5df9-81ce-a209ccbdcb07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['251b9e77-7989-55ff-b71a-12c3a0c97083', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3e54bc33-a75f-50a6-9a3f-699b9c7f6685', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4caa5049-8cfd-5822-95dd-80adf34b8341', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6ceb47fd-d396-5eca-b527-ea6c61e2119b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['c63b1222-783c-578f-bf08-2290574e900b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['179a8789-afeb-5502-a57a-770cbf30db55', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['81bff8b8-6fac-5a5c-8e81-27395eea14bc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['885d536c-f17f-5837-b8fa-ce13bcc4992f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['4d1b46b7-1239-5840-b608-4590bfc2178e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['d373e6e1-5bd3-5f83-8b42-799026988bf1', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['f596dded-3c13-54d2-afcc-5940bfac2c69', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['46854f60-ad43-51de-9af3-25d368ee1488', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['020c7ed4-e01c-543b-b728-62c2768fdb51', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['2c32d193-1165-5ad8-9dbb-303619d8a194', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['a67abb46-6efa-5c25-978c-90b72f708423', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['583c481f-5151-5f2c-af2c-82a6fb53c0d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['21d7eab8-2c4d-5418-976f-4f2a2c800b1b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['316a53ff-e67c-57e5-a376-357b288d5bb7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['0d2eeb41-053d-5aa6-b0ac-a82c1e023a3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), ELN Adverse Risk Group, Medulloblastoma, SHH-Activated"
0abac394-06e2-5d38-8845-8aca7485d7b5,https://www.mycancergenome.org/content/alteration/tp53-mutation/,TP53 Mutation," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Myeloid Sarcoma, Neuroblastoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Benign Fibrous Histiocytoma, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Colorectal Neoplasm, Gastric Carcinoma, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 175, 0,"[['f7b78afe-1dc1-544b-86ca-fc303608fe12', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['3a06b6c1-b916-585e-a8ee-bf0d44603555', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['d401d6ac-02de-5e98-9416-db7a5d609cae', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['11bbc0c7-e808-5c5b-b9a4-34854b768042', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['ecfb2c62-17f7-5a23-b492-04243f363a68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['50a3a24a-ffba-56d3-b0f4-dd00e66878f5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['144034da-587c-5a5c-91b8-88ba48987da8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['16bf36af-4f2b-51ae-a6b8-b1a112e0d541', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['92dbd658-5154-5f7c-bdac-452374dadf04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['4c48bf2b-8585-59aa-84c1-fed10995262c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['41d02d3c-8e93-5775-bc6d-2ba1db0df6b0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a9a7590f-c952-5fa5-899a-8d504e6636a6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['a778f5c1-738a-5249-b3e5-e2dfc385fc21', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['bceb75d4-b0e0-5d7c-ba19-d88de862ad90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6937de14-2dcc-5474-8d7e-c5f91fb0574f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['f11de56c-83c2-509d-8d13-4966c0a84f68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2cab8bcd-e3e2-5b6e-87ac-957239cf2b90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e52b77a9-4cb6-5fef-af5a-1fb74e535e3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['baf71877-bdd1-5a51-932c-ea31959c69ca', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['cb33e472-26d3-5149-8ca1-2b1218c5c31b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['22241703-06ed-5c36-a6fc-4f16f183620b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['1557f2bc-b966-526c-86c9-4fbee1673216', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['f6845d6d-32cc-5e48-950b-a2efb5bb76db', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['084c7c78-ac7a-5cb2-8307-dd942e9cd182', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['d7051af7-76a0-5bf9-8400-b10751bccf68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['4fd06ce5-42bf-522f-8fcc-8eabcce71cea', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['6aeabdb2-ae7c-5f4c-8084-53f8a1f439ac', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['2b86b372-c022-50ab-88d9-972cbaff3f20', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['10a68846-4ac9-59cc-a7bc-0788ddd03d30', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['c96141b1-b8c4-59fb-af26-5456e9fd0b42', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['449c6899-31a7-519a-8457-d268af25043a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['f1785909-382a-5e02-8dde-ea38e6b0843a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['56c9a226-5136-5a14-8948-47aa7b60182e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['29a19ae2-db0b-53e2-8a57-136850f3ac52', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['5d892867-dbff-551b-8ada-59265af845a8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5e54fb27-0e91-516c-9afd-c497eb96e45b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['01022853-10d1-5fe0-b6e7-05a02550d458', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['75467af3-5fe1-5e9f-b61c-687bc1f10aa2', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3875649e-f11b-559f-b059-04a2b0ee087a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['90ac98da-ede6-524a-810b-98386352229e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['14a7a77b-f7c5-5dfa-9675-d5d4bb667784', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['eee87161-3edc-530f-baba-ad74872676f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['08b0c502-82be-5e1d-80d6-e6686e97ccda', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['ed961ae2-c10b-528d-9d0f-55f37a52e778', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['ce12c206-947d-5653-974b-d4191b4649db', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['4eeebc62-194e-5fb3-bc14-ad8e21ba09ce', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['53feb50a-6a0f-599a-a954-309fbe9a0de9', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['a7a4a697-71d5-54c5-95e7-85092d33c719', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['e36e66ab-7a85-5362-bbeb-4cf163baacb3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['bfebf10b-d14b-549b-a038-d12227a0698e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['8ab4d815-2021-5168-9698-9562844d44f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03574402', 'Phase II Umbrella Study Directed by Next Generation Sequencing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03574402', ' Phase 2', ' BCL2L11, BCL2L11 Deletion,', ' Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma'], ['3c4e65b7-ec15-5774-95d5-49e9e37661fe', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['b7b55cf4-1a82-58c2-92a0-9b9c171b6d84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['aceef024-5e37-51c3-9933-c07d372fff13', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['283939cc-045c-583b-8586-c76358cdff5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['36ed3b2a-14bf-5c6a-99eb-4b4891340959', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia'], ['32413726-a315-5b7a-9b0c-d0b7e4efe582', 'https://www.mycancergenome.org/content/clinical_trials/NCT03466320', 'DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03466320', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['9df9fe36-0475-5beb-bb1b-ea38618261b4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03455517', 'Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03455517', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['6b105b72-f072-51af-a694-bca48a81fc74', 'https://www.mycancergenome.org/content/clinical_trials/NCT03454984', 'SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03454984', ' Phase 2', ' Complex karyotype, MECOM,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['45176428-ba01-57ec-93bf-a627b91c9d44', 'https://www.mycancergenome.org/content/clinical_trials/NCT03439371', 'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03439371', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), RB1 Mutation AND TP53 Mutation, ELN Adverse Risk Group"
c4073622-6381-5451-bfc5-0dc4d8f52685,https://www.mycancergenome.org/content/alteration/tp53-nonsense/,TP53 Nonsense," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['447f5fc0-9755-5554-9489-52bf792f5e5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['aed89f36-2dff-5e7a-9f3b-9694d21ff13c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['6c53b51c-ec0b-5963-be34-724106c30d40', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9b7526ff-6ce4-5147-972b-15c1d50cd667', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['7175024c-3075-5e83-ac67-913a6cef02da', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['f8f4db5c-b2b4-5bc8-b49a-ed430280f5ad', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['48f6a3a9-0168-55ba-bdab-650edb0c22c1', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['76893720-4f00-56f2-a36d-96319e39d6e3', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['0730948e-03fe-5b5a-b69c-b52ad0d99b62', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['693e3850-fbbb-5b63-bd6a-a160f9c427d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['0336585b-cdc2-5db7-b929-4e2de4341cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['a572b921-9c3e-5c8d-9334-28ce340d7721', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['f769fae4-c2db-56b1-8f68-2078597fcdf7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['72abd7ae-4680-5b64-a09b-380d5bd6bd2c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['dfa8f137-1a3b-568d-b0a3-092e25ba1e85', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
269b555a-95a5-5802-b6bb-c0a8c811507d,https://www.mycancergenome.org/content/alteration/tp53-c-1-c-137-missense/,TP53 c.1-c.137 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['c27e1b05-4b8a-5f12-b857-e86effb7b653', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['1e4d65ff-ce6b-5d92-9939-554bfb2e005a', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c8bc5be2-ea2d-576e-84b4-6aa027f56c49', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
3c6b1ac9-059f-5f3d-88bd-06d37472dd11,https://www.mycancergenome.org/content/alteration/tp53-c-142-c-212-missense/,TP53 c.142-c.212 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['659fd00d-ad10-56e6-b893-43e8f47719b7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['7ea0ac07-9f00-59fb-895a-094e1d5c2c27', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c9a756fc-ae49-567a-be17-8988dd44867c', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
7407edb4-03c5-5b25-ba9b-8742d62bc94e,https://www.mycancergenome.org/content/alteration/tp53-c-217-c-1178-missense/,TP53 c.217-c.1178 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['0629feba-d546-551e-b654-26f8bf9bfb92', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['a81fed8c-56f7-5f85-a75c-fa670584a139', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['7bc76597-92a2-5f63-a41d-9c48908cbb7e', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
eb6b3698-fb12-5db0-94a0-2b65a7a1096f,https://www.mycancergenome.org/content/alteration/tp53-frameshift/,TP53 Frameshift," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['773b840d-a0bf-54fa-8055-a2d50fd402d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['74e18afb-e0b6-5215-ba31-65ed711ed2f4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['e8ec27f2-cfb1-589b-b983-0b6963e9b98c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9a68f134-c3ed-58de-8d6e-d7faf3634ae7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['91d83c6b-d3b5-5180-adbf-f152b0873091', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['bdc5b528-c2bc-5ea1-a27a-cc6a20456106', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['7a3433d3-8a60-5ae6-bf27-caeb622041e9', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['f48415b8-7785-5024-8dc2-85513f4246a7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['75e44dd3-0602-570f-ab4d-ae1c844171ec', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4f4946c7-fa0e-59d2-a0b9-e39cce7a1c30', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['2a2e1ee8-7914-51be-9c9b-d2cfee7eb3c8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['09b9b4fb-7857-5fb3-b894-07c79a60c625', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['05d7ba44-424c-58f0-982e-3e6916ccfe2f', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['028ae3ba-5023-51d4-9dd3-1f96ca814984', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['517b5a62-0025-58b4-a78d-dfd21f9c36cf', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
c07a00ba-8a73-55f4-9c19-2fa957a8d589,https://www.mycancergenome.org/content/alteration/del-17-p13/,del(17)(p13)," Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 8, 3,"[['6fd5916f-f91a-55db-846a-b2245ff3ac60', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['65deaa23-b44d-5d89-8cbf-6a648e1dc914', 'https://www.mycancergenome.org/content/clinical_trials/NCT03943342', 'Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03943342', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia'], ['d293694e-f99f-573b-b2db-e4b36f2a4842', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['b4c0208e-2e42-5ba3-8ba1-f30f644087c7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03683277', 'IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03683277', ' Phase 2', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Multiple Myeloma'], ['a5d10f7a-517f-599c-bcb9-e2f5b8507ef7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03625388', 'Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03625388', ' Phase 2', ' ABL1, BCR, BCR-ABL1 Fusion,', ' Chronic Myeloid Leukemia'], ['616c00cc-7fcb-5879-8d95-0269a4730a9b', 'https://www.mycancergenome.org/content/clinical_trials/NCT02518555', 'Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02518555', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['5e60ba9f-207f-5696-8efa-14fdd2c1991d', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia']]"," 17p deletion group, del(11q), del(17p), or TP53 Missense Mutations"
edbc8f44-837f-5e73-9dae-161f44017d50,https://www.mycancergenome.org/content/alteration/tp53-codon-175-missense/,TP53 Codon 175 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['584f0cb2-196d-50cf-8571-5183f415f224', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'edbc8f44-837f-5e73-9dae-161f44017d50', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0dfd0073-1d59-5dce-b737-26b8fcdbe9ea,https://www.mycancergenome.org/content/alteration/tp53-codon-245-missense/,TP53 Codon 245 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['dc34c37f-0367-5489-9b23-cb1d28661739', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0dfd0073-1d59-5dce-b737-26b8fcdbe9ea', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
5aef6155-30cc-59d4-a900-af7b056d3c3e,https://www.mycancergenome.org/content/alteration/tp53-codon-248-missense/,TP53 Codon 248 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['0afacc31-c762-5ebb-bb29-30664eb6fbc5', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '5aef6155-30cc-59d4-a900-af7b056d3c3e', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
6ff8e186-58ca-5ded-98cd-228789184f15,https://www.mycancergenome.org/content/alteration/tp53-codon-273-missense/,TP53 Codon 273 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['f87e24bd-f06e-5fa0-bdb8-24b838509e84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '6ff8e186-58ca-5ded-98cd-228789184f15', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0ac59bdc-e47b-5e50-b8c2-856d5a528bd8,https://www.mycancergenome.org/content/alteration/tp53-codon-282-missense/,TP53 Codon 282 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['8e886948-d266-5c63-926a-8c04ab73b6af', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0ac59bdc-e47b-5e50-b8c2-856d5a528bd8', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
9fe84676-1bef-5cdc-95c3-c33f9658209f,https://www.mycancergenome.org/content/alteration/tp53-k132e/,TP53 K132E," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['148b646c-d6b4-59c7-a3e9-efbf1ac76504', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '9fe84676-1bef-5cdc-95c3-c33f9658209f', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
f60c488b-723e-5350-9c5b-d446d1f06e17,https://www.mycancergenome.org/content/alteration/tp53-k132n/,TP53 K132N," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['6dfa7e28-f1fc-5a15-aee9-7edfa1184520', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'f60c488b-723e-5350-9c5b-d446d1f06e17', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
6c2f74c4-62ff-5a6f-9bee-12723a40c35c,https://www.mycancergenome.org/content/alteration/tp53-mutation-germline/,TP53 Mutation (germline)," Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 8, 0,"[['e19c8958-eb02-52ca-bab7-53f3124d8153', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['e0f0c0f4-1363-53e8-899f-3e2d79718c6e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['c7a91999-5725-55bd-83d1-7c209364e848', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['5c3cfa58-e935-5fc1-a630-258099566f11', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['29323168-40ca-5422-ab24-b1061b7229f8', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['eca0ca48-eac3-527d-8f54-a1729ec5c75c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['f96380a3-fd32-5ebf-868d-5596fae3254c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['519bcf36-7c4d-5c6c-bf85-b245f1d57ced', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, SHH-Activated"
11717967-8881-51cf-a961-88598085ee04,https://www.mycancergenome.org/content/alteration/tp53-mutation-somatic/,TP53 Mutation (somatic)," Desmoplastic/Nodular Medulloblastoma, Gastric Adenocarcinoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 11, 0,"[['3b63dd08-f5ba-58b4-8b8d-f85a8d7e528f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['022e5e3a-262c-5e1c-843f-15f420b2624b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', '11717967-8881-51cf-a961-88598085ee04', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['c9ca4d40-cff8-5c8b-b27e-9a666a82f338', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['7fd24b12-032f-51e0-a186-6362520513b2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['32cc1a7a-4e80-591e-9047-3c483dea866b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['c9ab85ca-9b50-56bb-be65-7d5229f9c9fc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '11717967-8881-51cf-a961-88598085ee04', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['4f7f8a46-7499-583b-b7b9-813aae4d42fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '11717967-8881-51cf-a961-88598085ee04', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['7400aefa-8a50-5e85-9e3d-1e8a61c86384', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['6018fcaf-b49b-51c5-b441-4e8bd9bc9711', 'https://www.mycancergenome.org/content/clinical_trials/NCT02724579', 'Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT02724579', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma, Medulloblastoma, WNT-Activated'], ['3b6b479e-8f1e-58b2-9e19-d7d538412042', 'https://www.mycancergenome.org/content/clinical_trials/NCT02013154', 'A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab', '11717967-8881-51cf-a961-88598085ee04', ' NCT02013154', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma'], ['dc079969-9043-5f4d-af91-57931a18eb8f', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, WNT-Activated, Medulloblastoma, SHH-Activated"
20e3d8de-fee4-5710-9a2f-145210efff46,https://www.mycancergenome.org/content/alteration/tp53-r213l/,TP53 R213L," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['92888025-0cce-5e87-82f6-67004081fea6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '20e3d8de-fee4-5710-9a2f-145210efff46', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
72131208-da0f-5c55-99a3-c88e15ed0a71,https://www.mycancergenome.org/content/alteration/tp53-r249m/,TP53 R249M," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['43092bc5-b3db-5ce5-ab96-f302057e397d', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '72131208-da0f-5c55-99a3-c88e15ed0a71', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
bc65d8c8-e567-5949-af0f-81f840377a28,https://www.mycancergenome.org/content/alteration/tp53-s127y/,TP53 S127Y," Non-Small Cell Lung Carcinoma, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Malignant Solid Tumor, Lung Adenocarcinoma",, 1, 0,"[['5518a982-5ff1-509e-96f7-6d17bdc3a55f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'bc65d8c8-e567-5949-af0f-81f840377a28', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
854b04ef-860e-5032-b50c-b5a060ed67ae,https://www.mycancergenome.org/content/alteration/tp53-y220c/,TP53 Y220C," Malignant Breast Neoplasm, Non-Small Cell Lung Carcinoma, Malignant Ovarian Neoplasm, Hepatocellular Carcinoma, Squamous Cell Lung Carcinoma, Breast Ductal Carcinoma, Malignant Solid Tumor",, 1, 0,"[['62ffef8e-2268-5b72-a675-c67edb7e3044', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', '854b04ef-860e-5032-b50c-b5a060ed67ae', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor']]", None
7dee88b4-961c-53a3-b563-e2846809c859,https://www.mycancergenome.org/content/alteration/tp53-a119g/,TP53 A119G, None,,,,, None
20136a06-08ff-5b24-b177-42291df5b683,https://www.mycancergenome.org/content/alteration/tp53-a138p/,TP53 A138P, None,,,,, None
6ad6a957-ce71-59e3-b9c6-b8a6db9d5c4e,https://www.mycancergenome.org/content/alteration/tp53-a138v/,TP53 A138V, None,,,,, None
04059791-188f-5507-a141-41756021cb9e,https://www.mycancergenome.org/content/alteration/tp53-a159d/,TP53 A159D, None,,,,, None
8127c4d0-4f76-52a3-8c0f-482ac205712d,https://www.mycancergenome.org/content/alteration/tp53-a159p/,TP53 A159P, None,,,,, None
ec85f991-429a-55c0-9ade-fc7c5d2b93f4,https://www.mycancergenome.org/content/alteration/tp53-a159v/,TP53 A159V, None,,,,, None
cfbd00b2-3cc2-5ab1-a645-e64d44f68dcf,https://www.mycancergenome.org/content/alteration/tp53-a161d/,TP53 A161D, None,,,,, None
7af531a2-228f-566d-b2b7-aa9333a600c2,https://www.mycancergenome.org/content/alteration/tp53-a161s/,TP53 A161S, None,,,,, None
,Link,Biomarkers,Diseases,Pathways,Clinical_Trials,Drugs,ClinicalTrialsTitle,Alteration_Groups
c76e588f-080a-5f4e-a338-955130da287d,https://www.mycancergenome.org/content/gene/tp53/,TP53," Cancer, Vaginal Carcinoma, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Neuroblastoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Transitional Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Large Cell Lung Carcinoma, Clear Cell Renal Cell Carcinoma, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Acute Lymphoblastic Leukemia, Vulvar Carcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Hepatocellular Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Pancreatic Ductal Adenocarcinoma, Lymphoma, Malignant Peritoneal Neoplasm, Malignant Bladder Neoplasm, Benign Fibrous Histiocytoma, Malignant Head and Neck Neoplasm, Acute Myeloid Leukemia, Malignant Solid Tumor, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Breast Ductal Carcinoma, Anal Carcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Fallopian Tube Neoplasm, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Colon Neuroendocrine Neoplasm, Histiocytic And Dendritic Cell Cancer, Urothelial Carcinoma, Malignant Ovarian Epithelial Tumor", Cell cycle control, 206, 3,"[['8920c079-a6c0-5fa5-b5f0-aadce7ec0867', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['559d2f86-2a79-5e97-8b86-cbf90fa17ba6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['b0b04d8b-edba-56eb-9e00-1b5a069e185c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['c927ab37-1d1d-5755-a154-c18253fd367c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['686de7ed-a069-5fbb-9d0b-849398d393d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['97d2d07b-8fb4-55a5-8fae-682c4a5a091b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['1d8ef049-8e73-57c1-a414-127323b655d8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['edeb4236-f82c-56ac-b5bb-a7b247a407d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['81d544bf-76fa-5126-8bc4-ae12ff849510', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['2891c7b5-4548-5bc3-8cc1-ce2024027b6c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['428ca4a8-a020-51fe-8ed8-d1ee814d4a6f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor'], ['ef049a6e-21af-54d6-b69f-cfc4ab9b484c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['f876db17-7031-590a-80b8-f05f6b93cc07', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['3c6ec96c-d51b-53d2-b5e7-abd3106c6254', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['d0a1923a-945e-5758-bad0-7d964e2242f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['47faa36b-f117-52a2-a0c7-4a748fa30bfa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['0634f789-b86b-571a-922b-51d066058198', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['37ae8aef-3ce7-5a6a-8f0d-37c04d0c9b32', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['f435a5bb-177c-5d46-b831-b10d177b9d8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['bc6695f6-352a-5dd5-94b6-5b9dc00fd71a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2efa4aac-8164-5bff-a495-6626467a2375', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['8104b769-6031-50d3-b783-7379c93cd6c0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['7ac4e91c-40fa-5342-b988-2af33f945e67', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['77e2ffd3-7719-58e6-a1f5-3759cf00b74e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['aa95ff76-4526-5f44-8e9a-61d09c518749', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['555105c4-6ee2-5266-904d-244146ba85dd', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['1e6a42d4-1d17-5c82-8efd-a17d01604406', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a26b4e11-e0b1-5036-978d-8465070587cb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3da6e26f-c7ec-5113-805b-80b7302eae6b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['f1e66d04-9749-5f61-97d1-424ae2704448', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['8290b969-52fd-5ab6-a2a3-1dd845c68233', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a27cb61-7185-5eaa-b87b-ae2ba0387fa6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['ae756cad-e710-556d-b5ef-5e22ca23ae04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d0a5d9a6-03a3-5abd-a01f-92a1e71e0984', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['cfe127b9-93ba-5b83-986a-5a2a6ecca130', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['ddc6a312-3031-53c5-965e-94ac74f8b6aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['403dc844-4a13-5dc9-8d44-8bc4aaa0ffb1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['0adf2c15-fc9b-5c1e-8a0d-2b60253f9b4d', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['cf8e4c89-da0d-5e84-97dd-c0f4646a4166', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['526098fa-0c19-5bac-b9ec-1d29111862ab', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e51fc27a-baaa-58b8-8df6-6c5b2f8d984c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['4d3e8616-9c78-5e7c-a1cd-393769c71c90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['df545b25-510a-5a03-882f-6026d5665f0b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['9b29392c-b012-51ea-88bc-4a024dfc2c07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma'], ['f94ad441-3d98-53ac-a220-858c6ea23745', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c3c0333f-9623-53d2-bd07-3558d3ad0247', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['d7166f7a-728e-5550-82f1-b6c76863f2aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6e6afa2f-0af9-5d89-80fe-3442ce365909', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['b37fb9cc-bf33-5e4a-8c7f-1284f96e0926', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['f25dfe3b-b863-5ca3-96e0-a07dc5aa7dd4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['7c6bd3fa-b534-5f32-913c-13efe09a988c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['46d8d3b9-c1ba-505c-8c0b-277178274475', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['23ba20e7-a04f-5f1e-b7c3-05a463a80d4c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['5395e287-c588-5e7d-9705-05cf7638f0be', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['2857f779-7074-5887-9fb5-17ee5d67ea79', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['8476f372-4407-577a-a1e5-10066857162e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['ed558021-a193-5cd4-a0f1-2dfec163d38e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma'], ['12d2c9ee-8d91-574a-97ee-8c3ac141e289', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['7d56363c-3ca4-5237-a7c7-cb9d80ae5608', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['4b4e37a4-3dcb-5af1-9205-88e209220850', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts']]",
eba36364-821f-5f60-b93e-4857edc625ee,https://www.mycancergenome.org/content/alteration/tp53-loss/,TP53 Loss," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Ovarian Serous Tumor, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Malignant Bladder Neoplasm, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 187, 0,"[['e221663b-5a35-5781-bbd3-acada7f46f8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['75cd3142-59f8-5caf-adab-dad872fbc7f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['7c32e385-22e4-5688-819c-4219039fda73', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['507a6b75-20dd-5e8d-abb2-b8196882db5c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['762c33e0-037f-553d-b2b4-c73d4af3b9d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['ca08e81b-64ec-5e41-b861-3d109aaed50a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4b2e40ed-67de-5c6c-9834-d80205751186', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['1f4561b8-5862-59fe-a960-ee52834e42c3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['c64afea7-5389-5d3a-98f7-0d22257d5bad', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['58779054-877f-5d9e-a552-42ecde884ed0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['35a2a8e4-de0f-59af-b5dd-f26637c7c010', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6b268729-eb67-5362-bb67-d48a43d0e20e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a4621e3f-3a6e-51bd-9cd6-117a397a7a03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['19f47721-6769-514d-9ce5-a8647c3c7258', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['69481b88-9661-5764-9f6e-ff06e1afbca5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['2636aeed-9b11-55de-888e-4840f09a44df', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['2e51066e-ca32-5524-83a2-0f6ff1cd1cd6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['82575ecc-4aeb-5cdb-b9ce-aac82265f105', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['c0c1e6c1-eac2-5830-a7f1-2af3091f8b99', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5ef759a2-1f77-5835-a0a4-a9bd3ae96f03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['9063a22a-c9e8-5ed5-a226-f08e49d1be47', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['6fbe5e54-7397-5c5a-afa2-b5f980f4d677', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['30396263-e633-5e5b-b2f9-e36d15940e39', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c53a462b-1d08-54f5-bb73-df53c3f7caf5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['62d5ae16-1908-5a7d-93c4-adf601d0148f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a2d4906-7ff2-52da-aa03-879b446eb5d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a3c95bdb-87df-5825-bcf4-3d547ca4a9b1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['5a92b405-dcbc-5857-bd97-16d00864c6fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['d6153efa-d93e-5939-9290-a4fddd864cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['4153cbc8-adb3-556b-a0ea-195e9a842928', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['6c369150-0ca4-5ea1-8c34-0efaea36c614', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d8777ca4-4beb-59d6-97df-02633de11587', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['1e8bd600-5a56-54a2-9f95-861a142ea82f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['510aaf02-415b-58c8-b95b-a6ed6e122e68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4c8949f0-9984-5c33-a764-737c02d3d529', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['24ba6965-b932-5e56-a39d-7c688648f3d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f7b4e5ac-0098-50ef-a807-85c14ad681c2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['92f18279-c687-5cc4-b720-47734b22ae3f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f4aa0065-93a7-582f-b025-98d3908c5a94', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['f5ffe9a2-2a95-5e84-8469-51090a0449a1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['f001c121-0641-5df9-81ce-a209ccbdcb07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['251b9e77-7989-55ff-b71a-12c3a0c97083', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3e54bc33-a75f-50a6-9a3f-699b9c7f6685', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4caa5049-8cfd-5822-95dd-80adf34b8341', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6ceb47fd-d396-5eca-b527-ea6c61e2119b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['c63b1222-783c-578f-bf08-2290574e900b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['179a8789-afeb-5502-a57a-770cbf30db55', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['81bff8b8-6fac-5a5c-8e81-27395eea14bc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['885d536c-f17f-5837-b8fa-ce13bcc4992f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['4d1b46b7-1239-5840-b608-4590bfc2178e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['d373e6e1-5bd3-5f83-8b42-799026988bf1', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['f596dded-3c13-54d2-afcc-5940bfac2c69', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['46854f60-ad43-51de-9af3-25d368ee1488', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['020c7ed4-e01c-543b-b728-62c2768fdb51', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['2c32d193-1165-5ad8-9dbb-303619d8a194', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['a67abb46-6efa-5c25-978c-90b72f708423', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['583c481f-5151-5f2c-af2c-82a6fb53c0d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['21d7eab8-2c4d-5418-976f-4f2a2c800b1b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['316a53ff-e67c-57e5-a376-357b288d5bb7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['0d2eeb41-053d-5aa6-b0ac-a82c1e023a3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), ELN Adverse Risk Group, Medulloblastoma, SHH-Activated"
0abac394-06e2-5d38-8845-8aca7485d7b5,https://www.mycancergenome.org/content/alteration/tp53-mutation/,TP53 Mutation," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Myeloid Sarcoma, Neuroblastoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Benign Fibrous Histiocytoma, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Colorectal Neoplasm, Gastric Carcinoma, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 175, 0,"[['f7b78afe-1dc1-544b-86ca-fc303608fe12', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['3a06b6c1-b916-585e-a8ee-bf0d44603555', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['d401d6ac-02de-5e98-9416-db7a5d609cae', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['11bbc0c7-e808-5c5b-b9a4-34854b768042', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['ecfb2c62-17f7-5a23-b492-04243f363a68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['50a3a24a-ffba-56d3-b0f4-dd00e66878f5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['144034da-587c-5a5c-91b8-88ba48987da8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['16bf36af-4f2b-51ae-a6b8-b1a112e0d541', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['92dbd658-5154-5f7c-bdac-452374dadf04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['4c48bf2b-8585-59aa-84c1-fed10995262c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['41d02d3c-8e93-5775-bc6d-2ba1db0df6b0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a9a7590f-c952-5fa5-899a-8d504e6636a6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['a778f5c1-738a-5249-b3e5-e2dfc385fc21', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['bceb75d4-b0e0-5d7c-ba19-d88de862ad90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6937de14-2dcc-5474-8d7e-c5f91fb0574f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['f11de56c-83c2-509d-8d13-4966c0a84f68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2cab8bcd-e3e2-5b6e-87ac-957239cf2b90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e52b77a9-4cb6-5fef-af5a-1fb74e535e3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['baf71877-bdd1-5a51-932c-ea31959c69ca', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['cb33e472-26d3-5149-8ca1-2b1218c5c31b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['22241703-06ed-5c36-a6fc-4f16f183620b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['1557f2bc-b966-526c-86c9-4fbee1673216', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['f6845d6d-32cc-5e48-950b-a2efb5bb76db', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['084c7c78-ac7a-5cb2-8307-dd942e9cd182', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['d7051af7-76a0-5bf9-8400-b10751bccf68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['4fd06ce5-42bf-522f-8fcc-8eabcce71cea', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['6aeabdb2-ae7c-5f4c-8084-53f8a1f439ac', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['2b86b372-c022-50ab-88d9-972cbaff3f20', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['10a68846-4ac9-59cc-a7bc-0788ddd03d30', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['c96141b1-b8c4-59fb-af26-5456e9fd0b42', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['449c6899-31a7-519a-8457-d268af25043a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['f1785909-382a-5e02-8dde-ea38e6b0843a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['56c9a226-5136-5a14-8948-47aa7b60182e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['29a19ae2-db0b-53e2-8a57-136850f3ac52', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['5d892867-dbff-551b-8ada-59265af845a8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5e54fb27-0e91-516c-9afd-c497eb96e45b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['01022853-10d1-5fe0-b6e7-05a02550d458', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['75467af3-5fe1-5e9f-b61c-687bc1f10aa2', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3875649e-f11b-559f-b059-04a2b0ee087a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['90ac98da-ede6-524a-810b-98386352229e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['14a7a77b-f7c5-5dfa-9675-d5d4bb667784', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['eee87161-3edc-530f-baba-ad74872676f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['08b0c502-82be-5e1d-80d6-e6686e97ccda', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['ed961ae2-c10b-528d-9d0f-55f37a52e778', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['ce12c206-947d-5653-974b-d4191b4649db', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['4eeebc62-194e-5fb3-bc14-ad8e21ba09ce', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['53feb50a-6a0f-599a-a954-309fbe9a0de9', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['a7a4a697-71d5-54c5-95e7-85092d33c719', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['e36e66ab-7a85-5362-bbeb-4cf163baacb3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['bfebf10b-d14b-549b-a038-d12227a0698e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['8ab4d815-2021-5168-9698-9562844d44f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03574402', 'Phase II Umbrella Study Directed by Next Generation Sequencing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03574402', ' Phase 2', ' BCL2L11, BCL2L11 Deletion,', ' Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma'], ['3c4e65b7-ec15-5774-95d5-49e9e37661fe', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['b7b55cf4-1a82-58c2-92a0-9b9c171b6d84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['aceef024-5e37-51c3-9933-c07d372fff13', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['283939cc-045c-583b-8586-c76358cdff5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['36ed3b2a-14bf-5c6a-99eb-4b4891340959', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia'], ['32413726-a315-5b7a-9b0c-d0b7e4efe582', 'https://www.mycancergenome.org/content/clinical_trials/NCT03466320', 'DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03466320', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['9df9fe36-0475-5beb-bb1b-ea38618261b4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03455517', 'Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03455517', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['6b105b72-f072-51af-a694-bca48a81fc74', 'https://www.mycancergenome.org/content/clinical_trials/NCT03454984', 'SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03454984', ' Phase 2', ' Complex karyotype, MECOM,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['45176428-ba01-57ec-93bf-a627b91c9d44', 'https://www.mycancergenome.org/content/clinical_trials/NCT03439371', 'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03439371', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), RB1 Mutation AND TP53 Mutation, ELN Adverse Risk Group"
c4073622-6381-5451-bfc5-0dc4d8f52685,https://www.mycancergenome.org/content/alteration/tp53-nonsense/,TP53 Nonsense," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['447f5fc0-9755-5554-9489-52bf792f5e5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['aed89f36-2dff-5e7a-9f3b-9694d21ff13c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['6c53b51c-ec0b-5963-be34-724106c30d40', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9b7526ff-6ce4-5147-972b-15c1d50cd667', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['7175024c-3075-5e83-ac67-913a6cef02da', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['f8f4db5c-b2b4-5bc8-b49a-ed430280f5ad', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['48f6a3a9-0168-55ba-bdab-650edb0c22c1', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['76893720-4f00-56f2-a36d-96319e39d6e3', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['0730948e-03fe-5b5a-b69c-b52ad0d99b62', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['693e3850-fbbb-5b63-bd6a-a160f9c427d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['0336585b-cdc2-5db7-b929-4e2de4341cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['a572b921-9c3e-5c8d-9334-28ce340d7721', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['f769fae4-c2db-56b1-8f68-2078597fcdf7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['72abd7ae-4680-5b64-a09b-380d5bd6bd2c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['dfa8f137-1a3b-568d-b0a3-092e25ba1e85', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
269b555a-95a5-5802-b6bb-c0a8c811507d,https://www.mycancergenome.org/content/alteration/tp53-c-1-c-137-missense/,TP53 c.1-c.137 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['c27e1b05-4b8a-5f12-b857-e86effb7b653', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['1e4d65ff-ce6b-5d92-9939-554bfb2e005a', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c8bc5be2-ea2d-576e-84b4-6aa027f56c49', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
3c6b1ac9-059f-5f3d-88bd-06d37472dd11,https://www.mycancergenome.org/content/alteration/tp53-c-142-c-212-missense/,TP53 c.142-c.212 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['659fd00d-ad10-56e6-b893-43e8f47719b7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['7ea0ac07-9f00-59fb-895a-094e1d5c2c27', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c9a756fc-ae49-567a-be17-8988dd44867c', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
7407edb4-03c5-5b25-ba9b-8742d62bc94e,https://www.mycancergenome.org/content/alteration/tp53-c-217-c-1178-missense/,TP53 c.217-c.1178 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['0629feba-d546-551e-b654-26f8bf9bfb92', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['a81fed8c-56f7-5f85-a75c-fa670584a139', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['7bc76597-92a2-5f63-a41d-9c48908cbb7e', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
eb6b3698-fb12-5db0-94a0-2b65a7a1096f,https://www.mycancergenome.org/content/alteration/tp53-frameshift/,TP53 Frameshift," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['773b840d-a0bf-54fa-8055-a2d50fd402d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['74e18afb-e0b6-5215-ba31-65ed711ed2f4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['e8ec27f2-cfb1-589b-b983-0b6963e9b98c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9a68f134-c3ed-58de-8d6e-d7faf3634ae7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['91d83c6b-d3b5-5180-adbf-f152b0873091', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['bdc5b528-c2bc-5ea1-a27a-cc6a20456106', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['7a3433d3-8a60-5ae6-bf27-caeb622041e9', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['f48415b8-7785-5024-8dc2-85513f4246a7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['75e44dd3-0602-570f-ab4d-ae1c844171ec', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4f4946c7-fa0e-59d2-a0b9-e39cce7a1c30', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['2a2e1ee8-7914-51be-9c9b-d2cfee7eb3c8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['09b9b4fb-7857-5fb3-b894-07c79a60c625', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['05d7ba44-424c-58f0-982e-3e6916ccfe2f', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['028ae3ba-5023-51d4-9dd3-1f96ca814984', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['517b5a62-0025-58b4-a78d-dfd21f9c36cf', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
c07a00ba-8a73-55f4-9c19-2fa957a8d589,https://www.mycancergenome.org/content/alteration/del-17-p13/,del(17)(p13)," Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 8, 3,"[['6fd5916f-f91a-55db-846a-b2245ff3ac60', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['65deaa23-b44d-5d89-8cbf-6a648e1dc914', 'https://www.mycancergenome.org/content/clinical_trials/NCT03943342', 'Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03943342', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia'], ['d293694e-f99f-573b-b2db-e4b36f2a4842', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['b4c0208e-2e42-5ba3-8ba1-f30f644087c7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03683277', 'IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03683277', ' Phase 2', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Multiple Myeloma'], ['a5d10f7a-517f-599c-bcb9-e2f5b8507ef7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03625388', 'Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03625388', ' Phase 2', ' ABL1, BCR, BCR-ABL1 Fusion,', ' Chronic Myeloid Leukemia'], ['616c00cc-7fcb-5879-8d95-0269a4730a9b', 'https://www.mycancergenome.org/content/clinical_trials/NCT02518555', 'Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02518555', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['5e60ba9f-207f-5696-8efa-14fdd2c1991d', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia']]"," 17p deletion group, del(11q), del(17p), or TP53 Missense Mutations"
edbc8f44-837f-5e73-9dae-161f44017d50,https://www.mycancergenome.org/content/alteration/tp53-codon-175-missense/,TP53 Codon 175 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['584f0cb2-196d-50cf-8571-5183f415f224', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'edbc8f44-837f-5e73-9dae-161f44017d50', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0dfd0073-1d59-5dce-b737-26b8fcdbe9ea,https://www.mycancergenome.org/content/alteration/tp53-codon-245-missense/,TP53 Codon 245 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['dc34c37f-0367-5489-9b23-cb1d28661739', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0dfd0073-1d59-5dce-b737-26b8fcdbe9ea', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
5aef6155-30cc-59d4-a900-af7b056d3c3e,https://www.mycancergenome.org/content/alteration/tp53-codon-248-missense/,TP53 Codon 248 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['0afacc31-c762-5ebb-bb29-30664eb6fbc5', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '5aef6155-30cc-59d4-a900-af7b056d3c3e', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
6ff8e186-58ca-5ded-98cd-228789184f15,https://www.mycancergenome.org/content/alteration/tp53-codon-273-missense/,TP53 Codon 273 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['f87e24bd-f06e-5fa0-bdb8-24b838509e84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '6ff8e186-58ca-5ded-98cd-228789184f15', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0ac59bdc-e47b-5e50-b8c2-856d5a528bd8,https://www.mycancergenome.org/content/alteration/tp53-codon-282-missense/,TP53 Codon 282 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['8e886948-d266-5c63-926a-8c04ab73b6af', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0ac59bdc-e47b-5e50-b8c2-856d5a528bd8', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
9fe84676-1bef-5cdc-95c3-c33f9658209f,https://www.mycancergenome.org/content/alteration/tp53-k132e/,TP53 K132E," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['148b646c-d6b4-59c7-a3e9-efbf1ac76504', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '9fe84676-1bef-5cdc-95c3-c33f9658209f', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
f60c488b-723e-5350-9c5b-d446d1f06e17,https://www.mycancergenome.org/content/alteration/tp53-k132n/,TP53 K132N," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['6dfa7e28-f1fc-5a15-aee9-7edfa1184520', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'f60c488b-723e-5350-9c5b-d446d1f06e17', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
6c2f74c4-62ff-5a6f-9bee-12723a40c35c,https://www.mycancergenome.org/content/alteration/tp53-mutation-germline/,TP53 Mutation (germline)," Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 8, 0,"[['e19c8958-eb02-52ca-bab7-53f3124d8153', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['e0f0c0f4-1363-53e8-899f-3e2d79718c6e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['c7a91999-5725-55bd-83d1-7c209364e848', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['5c3cfa58-e935-5fc1-a630-258099566f11', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['29323168-40ca-5422-ab24-b1061b7229f8', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['eca0ca48-eac3-527d-8f54-a1729ec5c75c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['f96380a3-fd32-5ebf-868d-5596fae3254c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['519bcf36-7c4d-5c6c-bf85-b245f1d57ced', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, SHH-Activated"
11717967-8881-51cf-a961-88598085ee04,https://www.mycancergenome.org/content/alteration/tp53-mutation-somatic/,TP53 Mutation (somatic)," Desmoplastic/Nodular Medulloblastoma, Gastric Adenocarcinoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 11, 0,"[['3b63dd08-f5ba-58b4-8b8d-f85a8d7e528f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['022e5e3a-262c-5e1c-843f-15f420b2624b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', '11717967-8881-51cf-a961-88598085ee04', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['c9ca4d40-cff8-5c8b-b27e-9a666a82f338', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['7fd24b12-032f-51e0-a186-6362520513b2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['32cc1a7a-4e80-591e-9047-3c483dea866b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['c9ab85ca-9b50-56bb-be65-7d5229f9c9fc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '11717967-8881-51cf-a961-88598085ee04', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['4f7f8a46-7499-583b-b7b9-813aae4d42fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '11717967-8881-51cf-a961-88598085ee04', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['7400aefa-8a50-5e85-9e3d-1e8a61c86384', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['6018fcaf-b49b-51c5-b441-4e8bd9bc9711', 'https://www.mycancergenome.org/content/clinical_trials/NCT02724579', 'Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT02724579', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma, Medulloblastoma, WNT-Activated'], ['3b6b479e-8f1e-58b2-9e19-d7d538412042', 'https://www.mycancergenome.org/content/clinical_trials/NCT02013154', 'A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab', '11717967-8881-51cf-a961-88598085ee04', ' NCT02013154', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma'], ['dc079969-9043-5f4d-af91-57931a18eb8f', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, WNT-Activated, Medulloblastoma, SHH-Activated"
20e3d8de-fee4-5710-9a2f-145210efff46,https://www.mycancergenome.org/content/alteration/tp53-r213l/,TP53 R213L," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['92888025-0cce-5e87-82f6-67004081fea6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '20e3d8de-fee4-5710-9a2f-145210efff46', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
72131208-da0f-5c55-99a3-c88e15ed0a71,https://www.mycancergenome.org/content/alteration/tp53-r249m/,TP53 R249M," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['43092bc5-b3db-5ce5-ab96-f302057e397d', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '72131208-da0f-5c55-99a3-c88e15ed0a71', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
bc65d8c8-e567-5949-af0f-81f840377a28,https://www.mycancergenome.org/content/alteration/tp53-s127y/,TP53 S127Y," Non-Small Cell Lung Carcinoma, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Malignant Solid Tumor, Lung Adenocarcinoma",, 1, 0,"[['5518a982-5ff1-509e-96f7-6d17bdc3a55f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'bc65d8c8-e567-5949-af0f-81f840377a28', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
854b04ef-860e-5032-b50c-b5a060ed67ae,https://www.mycancergenome.org/content/alteration/tp53-y220c/,TP53 Y220C," Malignant Breast Neoplasm, Non-Small Cell Lung Carcinoma, Malignant Ovarian Neoplasm, Hepatocellular Carcinoma, Squamous Cell Lung Carcinoma, Breast Ductal Carcinoma, Malignant Solid Tumor",, 1, 0,"[['62ffef8e-2268-5b72-a675-c67edb7e3044', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', '854b04ef-860e-5032-b50c-b5a060ed67ae', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor']]", None
7dee88b4-961c-53a3-b563-e2846809c859,https://www.mycancergenome.org/content/alteration/tp53-a119g/,TP53 A119G, None,,,,, None
20136a06-08ff-5b24-b177-42291df5b683,https://www.mycancergenome.org/content/alteration/tp53-a138p/,TP53 A138P, None,,,,, None
6ad6a957-ce71-59e3-b9c6-b8a6db9d5c4e,https://www.mycancergenome.org/content/alteration/tp53-a138v/,TP53 A138V, None,,,,, None
04059791-188f-5507-a141-41756021cb9e,https://www.mycancergenome.org/content/alteration/tp53-a159d/,TP53 A159D, None,,,,, None
8127c4d0-4f76-52a3-8c0f-482ac205712d,https://www.mycancergenome.org/content/alteration/tp53-a159p/,TP53 A159P, None,,,,, None
ec85f991-429a-55c0-9ade-fc7c5d2b93f4,https://www.mycancergenome.org/content/alteration/tp53-a159v/,TP53 A159V, None,,,,, None
cfbd00b2-3cc2-5ab1-a645-e64d44f68dcf,https://www.mycancergenome.org/content/alteration/tp53-a161d/,TP53 A161D, None,,,,, None
7af531a2-228f-566d-b2b7-aa9333a600c2,https://www.mycancergenome.org/content/alteration/tp53-a161s/,TP53 A161S, None,,,,, None
,Link,Biomarkers,Diseases,Pathways,Clinical_Trials,Drugs,ClinicalTrialsTitle,Alteration_Groups
c76e588f-080a-5f4e-a338-955130da287d,https://www.mycancergenome.org/content/gene/tp53/,TP53," Cancer, Vaginal Carcinoma, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Neuroblastoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Transitional Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Large Cell Lung Carcinoma, Clear Cell Renal Cell Carcinoma, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Acute Lymphoblastic Leukemia, Vulvar Carcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Hepatocellular Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Pancreatic Ductal Adenocarcinoma, Lymphoma, Malignant Peritoneal Neoplasm, Malignant Bladder Neoplasm, Benign Fibrous Histiocytoma, Malignant Head and Neck Neoplasm, Acute Myeloid Leukemia, Malignant Solid Tumor, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Breast Ductal Carcinoma, Anal Carcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Fallopian Tube Neoplasm, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Colon Neuroendocrine Neoplasm, Histiocytic And Dendritic Cell Cancer, Urothelial Carcinoma, Malignant Ovarian Epithelial Tumor", Cell cycle control, 206, 3,"[['8920c079-a6c0-5fa5-b5f0-aadce7ec0867', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['559d2f86-2a79-5e97-8b86-cbf90fa17ba6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['b0b04d8b-edba-56eb-9e00-1b5a069e185c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['c927ab37-1d1d-5755-a154-c18253fd367c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['686de7ed-a069-5fbb-9d0b-849398d393d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['97d2d07b-8fb4-55a5-8fae-682c4a5a091b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['1d8ef049-8e73-57c1-a414-127323b655d8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['edeb4236-f82c-56ac-b5bb-a7b247a407d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['81d544bf-76fa-5126-8bc4-ae12ff849510', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['2891c7b5-4548-5bc3-8cc1-ce2024027b6c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['428ca4a8-a020-51fe-8ed8-d1ee814d4a6f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor'], ['ef049a6e-21af-54d6-b69f-cfc4ab9b484c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['f876db17-7031-590a-80b8-f05f6b93cc07', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['3c6ec96c-d51b-53d2-b5e7-abd3106c6254', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['d0a1923a-945e-5758-bad0-7d964e2242f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['47faa36b-f117-52a2-a0c7-4a748fa30bfa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['0634f789-b86b-571a-922b-51d066058198', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['37ae8aef-3ce7-5a6a-8f0d-37c04d0c9b32', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['f435a5bb-177c-5d46-b831-b10d177b9d8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['bc6695f6-352a-5dd5-94b6-5b9dc00fd71a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2efa4aac-8164-5bff-a495-6626467a2375', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['8104b769-6031-50d3-b783-7379c93cd6c0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['7ac4e91c-40fa-5342-b988-2af33f945e67', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['77e2ffd3-7719-58e6-a1f5-3759cf00b74e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['aa95ff76-4526-5f44-8e9a-61d09c518749', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['555105c4-6ee2-5266-904d-244146ba85dd', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['1e6a42d4-1d17-5c82-8efd-a17d01604406', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a26b4e11-e0b1-5036-978d-8465070587cb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3da6e26f-c7ec-5113-805b-80b7302eae6b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['f1e66d04-9749-5f61-97d1-424ae2704448', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['8290b969-52fd-5ab6-a2a3-1dd845c68233', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a27cb61-7185-5eaa-b87b-ae2ba0387fa6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['ae756cad-e710-556d-b5ef-5e22ca23ae04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d0a5d9a6-03a3-5abd-a01f-92a1e71e0984', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['cfe127b9-93ba-5b83-986a-5a2a6ecca130', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['ddc6a312-3031-53c5-965e-94ac74f8b6aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['403dc844-4a13-5dc9-8d44-8bc4aaa0ffb1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['0adf2c15-fc9b-5c1e-8a0d-2b60253f9b4d', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['cf8e4c89-da0d-5e84-97dd-c0f4646a4166', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['526098fa-0c19-5bac-b9ec-1d29111862ab', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e51fc27a-baaa-58b8-8df6-6c5b2f8d984c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['4d3e8616-9c78-5e7c-a1cd-393769c71c90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['df545b25-510a-5a03-882f-6026d5665f0b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['9b29392c-b012-51ea-88bc-4a024dfc2c07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma'], ['f94ad441-3d98-53ac-a220-858c6ea23745', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c3c0333f-9623-53d2-bd07-3558d3ad0247', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['d7166f7a-728e-5550-82f1-b6c76863f2aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6e6afa2f-0af9-5d89-80fe-3442ce365909', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['b37fb9cc-bf33-5e4a-8c7f-1284f96e0926', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['f25dfe3b-b863-5ca3-96e0-a07dc5aa7dd4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['7c6bd3fa-b534-5f32-913c-13efe09a988c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['46d8d3b9-c1ba-505c-8c0b-277178274475', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['23ba20e7-a04f-5f1e-b7c3-05a463a80d4c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['5395e287-c588-5e7d-9705-05cf7638f0be', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['2857f779-7074-5887-9fb5-17ee5d67ea79', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['8476f372-4407-577a-a1e5-10066857162e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['ed558021-a193-5cd4-a0f1-2dfec163d38e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma'], ['12d2c9ee-8d91-574a-97ee-8c3ac141e289', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['7d56363c-3ca4-5237-a7c7-cb9d80ae5608', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['4b4e37a4-3dcb-5af1-9205-88e209220850', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts']]",
eba36364-821f-5f60-b93e-4857edc625ee,https://www.mycancergenome.org/content/alteration/tp53-loss/,TP53 Loss," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Ovarian Serous Tumor, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Malignant Bladder Neoplasm, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 187, 0,"[['e221663b-5a35-5781-bbd3-acada7f46f8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['75cd3142-59f8-5caf-adab-dad872fbc7f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['7c32e385-22e4-5688-819c-4219039fda73', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['507a6b75-20dd-5e8d-abb2-b8196882db5c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['762c33e0-037f-553d-b2b4-c73d4af3b9d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['ca08e81b-64ec-5e41-b861-3d109aaed50a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4b2e40ed-67de-5c6c-9834-d80205751186', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['1f4561b8-5862-59fe-a960-ee52834e42c3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['c64afea7-5389-5d3a-98f7-0d22257d5bad', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['58779054-877f-5d9e-a552-42ecde884ed0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['35a2a8e4-de0f-59af-b5dd-f26637c7c010', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6b268729-eb67-5362-bb67-d48a43d0e20e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a4621e3f-3a6e-51bd-9cd6-117a397a7a03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['19f47721-6769-514d-9ce5-a8647c3c7258', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['69481b88-9661-5764-9f6e-ff06e1afbca5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['2636aeed-9b11-55de-888e-4840f09a44df', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['2e51066e-ca32-5524-83a2-0f6ff1cd1cd6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['82575ecc-4aeb-5cdb-b9ce-aac82265f105', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['c0c1e6c1-eac2-5830-a7f1-2af3091f8b99', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5ef759a2-1f77-5835-a0a4-a9bd3ae96f03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['9063a22a-c9e8-5ed5-a226-f08e49d1be47', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['6fbe5e54-7397-5c5a-afa2-b5f980f4d677', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['30396263-e633-5e5b-b2f9-e36d15940e39', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c53a462b-1d08-54f5-bb73-df53c3f7caf5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['62d5ae16-1908-5a7d-93c4-adf601d0148f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a2d4906-7ff2-52da-aa03-879b446eb5d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a3c95bdb-87df-5825-bcf4-3d547ca4a9b1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['5a92b405-dcbc-5857-bd97-16d00864c6fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['d6153efa-d93e-5939-9290-a4fddd864cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['4153cbc8-adb3-556b-a0ea-195e9a842928', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['6c369150-0ca4-5ea1-8c34-0efaea36c614', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d8777ca4-4beb-59d6-97df-02633de11587', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['1e8bd600-5a56-54a2-9f95-861a142ea82f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['510aaf02-415b-58c8-b95b-a6ed6e122e68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4c8949f0-9984-5c33-a764-737c02d3d529', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['24ba6965-b932-5e56-a39d-7c688648f3d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f7b4e5ac-0098-50ef-a807-85c14ad681c2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['92f18279-c687-5cc4-b720-47734b22ae3f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f4aa0065-93a7-582f-b025-98d3908c5a94', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['f5ffe9a2-2a95-5e84-8469-51090a0449a1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['f001c121-0641-5df9-81ce-a209ccbdcb07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['251b9e77-7989-55ff-b71a-12c3a0c97083', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3e54bc33-a75f-50a6-9a3f-699b9c7f6685', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4caa5049-8cfd-5822-95dd-80adf34b8341', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6ceb47fd-d396-5eca-b527-ea6c61e2119b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['c63b1222-783c-578f-bf08-2290574e900b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['179a8789-afeb-5502-a57a-770cbf30db55', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['81bff8b8-6fac-5a5c-8e81-27395eea14bc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['885d536c-f17f-5837-b8fa-ce13bcc4992f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['4d1b46b7-1239-5840-b608-4590bfc2178e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['d373e6e1-5bd3-5f83-8b42-799026988bf1', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['f596dded-3c13-54d2-afcc-5940bfac2c69', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['46854f60-ad43-51de-9af3-25d368ee1488', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['020c7ed4-e01c-543b-b728-62c2768fdb51', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['2c32d193-1165-5ad8-9dbb-303619d8a194', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['a67abb46-6efa-5c25-978c-90b72f708423', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['583c481f-5151-5f2c-af2c-82a6fb53c0d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['21d7eab8-2c4d-5418-976f-4f2a2c800b1b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['316a53ff-e67c-57e5-a376-357b288d5bb7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['0d2eeb41-053d-5aa6-b0ac-a82c1e023a3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), ELN Adverse Risk Group, Medulloblastoma, SHH-Activated"
0abac394-06e2-5d38-8845-8aca7485d7b5,https://www.mycancergenome.org/content/alteration/tp53-mutation/,TP53 Mutation," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Myeloid Sarcoma, Neuroblastoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Benign Fibrous Histiocytoma, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Colorectal Neoplasm, Gastric Carcinoma, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 175, 0,"[['f7b78afe-1dc1-544b-86ca-fc303608fe12', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['3a06b6c1-b916-585e-a8ee-bf0d44603555', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['d401d6ac-02de-5e98-9416-db7a5d609cae', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['11bbc0c7-e808-5c5b-b9a4-34854b768042', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['ecfb2c62-17f7-5a23-b492-04243f363a68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['50a3a24a-ffba-56d3-b0f4-dd00e66878f5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['144034da-587c-5a5c-91b8-88ba48987da8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['16bf36af-4f2b-51ae-a6b8-b1a112e0d541', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['92dbd658-5154-5f7c-bdac-452374dadf04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['4c48bf2b-8585-59aa-84c1-fed10995262c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['41d02d3c-8e93-5775-bc6d-2ba1db0df6b0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a9a7590f-c952-5fa5-899a-8d504e6636a6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['a778f5c1-738a-5249-b3e5-e2dfc385fc21', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['bceb75d4-b0e0-5d7c-ba19-d88de862ad90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6937de14-2dcc-5474-8d7e-c5f91fb0574f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['f11de56c-83c2-509d-8d13-4966c0a84f68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2cab8bcd-e3e2-5b6e-87ac-957239cf2b90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e52b77a9-4cb6-5fef-af5a-1fb74e535e3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['baf71877-bdd1-5a51-932c-ea31959c69ca', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['cb33e472-26d3-5149-8ca1-2b1218c5c31b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['22241703-06ed-5c36-a6fc-4f16f183620b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['1557f2bc-b966-526c-86c9-4fbee1673216', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['f6845d6d-32cc-5e48-950b-a2efb5bb76db', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['084c7c78-ac7a-5cb2-8307-dd942e9cd182', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['d7051af7-76a0-5bf9-8400-b10751bccf68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['4fd06ce5-42bf-522f-8fcc-8eabcce71cea', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['6aeabdb2-ae7c-5f4c-8084-53f8a1f439ac', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['2b86b372-c022-50ab-88d9-972cbaff3f20', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['10a68846-4ac9-59cc-a7bc-0788ddd03d30', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['c96141b1-b8c4-59fb-af26-5456e9fd0b42', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['449c6899-31a7-519a-8457-d268af25043a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['f1785909-382a-5e02-8dde-ea38e6b0843a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['56c9a226-5136-5a14-8948-47aa7b60182e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['29a19ae2-db0b-53e2-8a57-136850f3ac52', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['5d892867-dbff-551b-8ada-59265af845a8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5e54fb27-0e91-516c-9afd-c497eb96e45b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['01022853-10d1-5fe0-b6e7-05a02550d458', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['75467af3-5fe1-5e9f-b61c-687bc1f10aa2', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3875649e-f11b-559f-b059-04a2b0ee087a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['90ac98da-ede6-524a-810b-98386352229e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['14a7a77b-f7c5-5dfa-9675-d5d4bb667784', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['eee87161-3edc-530f-baba-ad74872676f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['08b0c502-82be-5e1d-80d6-e6686e97ccda', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['ed961ae2-c10b-528d-9d0f-55f37a52e778', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['ce12c206-947d-5653-974b-d4191b4649db', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['4eeebc62-194e-5fb3-bc14-ad8e21ba09ce', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['53feb50a-6a0f-599a-a954-309fbe9a0de9', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['a7a4a697-71d5-54c5-95e7-85092d33c719', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['e36e66ab-7a85-5362-bbeb-4cf163baacb3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['bfebf10b-d14b-549b-a038-d12227a0698e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['8ab4d815-2021-5168-9698-9562844d44f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03574402', 'Phase II Umbrella Study Directed by Next Generation Sequencing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03574402', ' Phase 2', ' BCL2L11, BCL2L11 Deletion,', ' Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma'], ['3c4e65b7-ec15-5774-95d5-49e9e37661fe', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['b7b55cf4-1a82-58c2-92a0-9b9c171b6d84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['aceef024-5e37-51c3-9933-c07d372fff13', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['283939cc-045c-583b-8586-c76358cdff5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['36ed3b2a-14bf-5c6a-99eb-4b4891340959', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia'], ['32413726-a315-5b7a-9b0c-d0b7e4efe582', 'https://www.mycancergenome.org/content/clinical_trials/NCT03466320', 'DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03466320', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['9df9fe36-0475-5beb-bb1b-ea38618261b4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03455517', 'Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03455517', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['6b105b72-f072-51af-a694-bca48a81fc74', 'https://www.mycancergenome.org/content/clinical_trials/NCT03454984', 'SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03454984', ' Phase 2', ' Complex karyotype, MECOM,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['45176428-ba01-57ec-93bf-a627b91c9d44', 'https://www.mycancergenome.org/content/clinical_trials/NCT03439371', 'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03439371', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), RB1 Mutation AND TP53 Mutation, ELN Adverse Risk Group"
c4073622-6381-5451-bfc5-0dc4d8f52685,https://www.mycancergenome.org/content/alteration/tp53-nonsense/,TP53 Nonsense," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['447f5fc0-9755-5554-9489-52bf792f5e5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['aed89f36-2dff-5e7a-9f3b-9694d21ff13c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['6c53b51c-ec0b-5963-be34-724106c30d40', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9b7526ff-6ce4-5147-972b-15c1d50cd667', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['7175024c-3075-5e83-ac67-913a6cef02da', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['f8f4db5c-b2b4-5bc8-b49a-ed430280f5ad', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['48f6a3a9-0168-55ba-bdab-650edb0c22c1', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['76893720-4f00-56f2-a36d-96319e39d6e3', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['0730948e-03fe-5b5a-b69c-b52ad0d99b62', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['693e3850-fbbb-5b63-bd6a-a160f9c427d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['0336585b-cdc2-5db7-b929-4e2de4341cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['a572b921-9c3e-5c8d-9334-28ce340d7721', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['f769fae4-c2db-56b1-8f68-2078597fcdf7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['72abd7ae-4680-5b64-a09b-380d5bd6bd2c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['dfa8f137-1a3b-568d-b0a3-092e25ba1e85', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
269b555a-95a5-5802-b6bb-c0a8c811507d,https://www.mycancergenome.org/content/alteration/tp53-c-1-c-137-missense/,TP53 c.1-c.137 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['c27e1b05-4b8a-5f12-b857-e86effb7b653', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['1e4d65ff-ce6b-5d92-9939-554bfb2e005a', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c8bc5be2-ea2d-576e-84b4-6aa027f56c49', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
3c6b1ac9-059f-5f3d-88bd-06d37472dd11,https://www.mycancergenome.org/content/alteration/tp53-c-142-c-212-missense/,TP53 c.142-c.212 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['659fd00d-ad10-56e6-b893-43e8f47719b7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['7ea0ac07-9f00-59fb-895a-094e1d5c2c27', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c9a756fc-ae49-567a-be17-8988dd44867c', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
7407edb4-03c5-5b25-ba9b-8742d62bc94e,https://www.mycancergenome.org/content/alteration/tp53-c-217-c-1178-missense/,TP53 c.217-c.1178 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['0629feba-d546-551e-b654-26f8bf9bfb92', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['a81fed8c-56f7-5f85-a75c-fa670584a139', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['7bc76597-92a2-5f63-a41d-9c48908cbb7e', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
eb6b3698-fb12-5db0-94a0-2b65a7a1096f,https://www.mycancergenome.org/content/alteration/tp53-frameshift/,TP53 Frameshift," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['773b840d-a0bf-54fa-8055-a2d50fd402d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['74e18afb-e0b6-5215-ba31-65ed711ed2f4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['e8ec27f2-cfb1-589b-b983-0b6963e9b98c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9a68f134-c3ed-58de-8d6e-d7faf3634ae7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['91d83c6b-d3b5-5180-adbf-f152b0873091', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['bdc5b528-c2bc-5ea1-a27a-cc6a20456106', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['7a3433d3-8a60-5ae6-bf27-caeb622041e9', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['f48415b8-7785-5024-8dc2-85513f4246a7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['75e44dd3-0602-570f-ab4d-ae1c844171ec', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4f4946c7-fa0e-59d2-a0b9-e39cce7a1c30', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['2a2e1ee8-7914-51be-9c9b-d2cfee7eb3c8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['09b9b4fb-7857-5fb3-b894-07c79a60c625', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['05d7ba44-424c-58f0-982e-3e6916ccfe2f', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['028ae3ba-5023-51d4-9dd3-1f96ca814984', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['517b5a62-0025-58b4-a78d-dfd21f9c36cf', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
c07a00ba-8a73-55f4-9c19-2fa957a8d589,https://www.mycancergenome.org/content/alteration/del-17-p13/,del(17)(p13)," Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 8, 3,"[['6fd5916f-f91a-55db-846a-b2245ff3ac60', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['65deaa23-b44d-5d89-8cbf-6a648e1dc914', 'https://www.mycancergenome.org/content/clinical_trials/NCT03943342', 'Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03943342', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia'], ['d293694e-f99f-573b-b2db-e4b36f2a4842', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['b4c0208e-2e42-5ba3-8ba1-f30f644087c7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03683277', 'IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03683277', ' Phase 2', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Multiple Myeloma'], ['a5d10f7a-517f-599c-bcb9-e2f5b8507ef7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03625388', 'Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03625388', ' Phase 2', ' ABL1, BCR, BCR-ABL1 Fusion,', ' Chronic Myeloid Leukemia'], ['616c00cc-7fcb-5879-8d95-0269a4730a9b', 'https://www.mycancergenome.org/content/clinical_trials/NCT02518555', 'Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02518555', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['5e60ba9f-207f-5696-8efa-14fdd2c1991d', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia']]"," 17p deletion group, del(11q), del(17p), or TP53 Missense Mutations"
edbc8f44-837f-5e73-9dae-161f44017d50,https://www.mycancergenome.org/content/alteration/tp53-codon-175-missense/,TP53 Codon 175 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['584f0cb2-196d-50cf-8571-5183f415f224', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'edbc8f44-837f-5e73-9dae-161f44017d50', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0dfd0073-1d59-5dce-b737-26b8fcdbe9ea,https://www.mycancergenome.org/content/alteration/tp53-codon-245-missense/,TP53 Codon 245 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['dc34c37f-0367-5489-9b23-cb1d28661739', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0dfd0073-1d59-5dce-b737-26b8fcdbe9ea', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
5aef6155-30cc-59d4-a900-af7b056d3c3e,https://www.mycancergenome.org/content/alteration/tp53-codon-248-missense/,TP53 Codon 248 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['0afacc31-c762-5ebb-bb29-30664eb6fbc5', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '5aef6155-30cc-59d4-a900-af7b056d3c3e', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
6ff8e186-58ca-5ded-98cd-228789184f15,https://www.mycancergenome.org/content/alteration/tp53-codon-273-missense/,TP53 Codon 273 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['f87e24bd-f06e-5fa0-bdb8-24b838509e84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '6ff8e186-58ca-5ded-98cd-228789184f15', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0ac59bdc-e47b-5e50-b8c2-856d5a528bd8,https://www.mycancergenome.org/content/alteration/tp53-codon-282-missense/,TP53 Codon 282 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['8e886948-d266-5c63-926a-8c04ab73b6af', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0ac59bdc-e47b-5e50-b8c2-856d5a528bd8', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
9fe84676-1bef-5cdc-95c3-c33f9658209f,https://www.mycancergenome.org/content/alteration/tp53-k132e/,TP53 K132E," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['148b646c-d6b4-59c7-a3e9-efbf1ac76504', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '9fe84676-1bef-5cdc-95c3-c33f9658209f', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
f60c488b-723e-5350-9c5b-d446d1f06e17,https://www.mycancergenome.org/content/alteration/tp53-k132n/,TP53 K132N," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['6dfa7e28-f1fc-5a15-aee9-7edfa1184520', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'f60c488b-723e-5350-9c5b-d446d1f06e17', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
6c2f74c4-62ff-5a6f-9bee-12723a40c35c,https://www.mycancergenome.org/content/alteration/tp53-mutation-germline/,TP53 Mutation (germline)," Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 8, 0,"[['e19c8958-eb02-52ca-bab7-53f3124d8153', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['e0f0c0f4-1363-53e8-899f-3e2d79718c6e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['c7a91999-5725-55bd-83d1-7c209364e848', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['5c3cfa58-e935-5fc1-a630-258099566f11', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['29323168-40ca-5422-ab24-b1061b7229f8', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['eca0ca48-eac3-527d-8f54-a1729ec5c75c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['f96380a3-fd32-5ebf-868d-5596fae3254c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['519bcf36-7c4d-5c6c-bf85-b245f1d57ced', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, SHH-Activated"
11717967-8881-51cf-a961-88598085ee04,https://www.mycancergenome.org/content/alteration/tp53-mutation-somatic/,TP53 Mutation (somatic)," Desmoplastic/Nodular Medulloblastoma, Gastric Adenocarcinoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 11, 0,"[['3b63dd08-f5ba-58b4-8b8d-f85a8d7e528f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['022e5e3a-262c-5e1c-843f-15f420b2624b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', '11717967-8881-51cf-a961-88598085ee04', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['c9ca4d40-cff8-5c8b-b27e-9a666a82f338', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['7fd24b12-032f-51e0-a186-6362520513b2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['32cc1a7a-4e80-591e-9047-3c483dea866b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['c9ab85ca-9b50-56bb-be65-7d5229f9c9fc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '11717967-8881-51cf-a961-88598085ee04', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['4f7f8a46-7499-583b-b7b9-813aae4d42fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '11717967-8881-51cf-a961-88598085ee04', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['7400aefa-8a50-5e85-9e3d-1e8a61c86384', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['6018fcaf-b49b-51c5-b441-4e8bd9bc9711', 'https://www.mycancergenome.org/content/clinical_trials/NCT02724579', 'Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT02724579', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma, Medulloblastoma, WNT-Activated'], ['3b6b479e-8f1e-58b2-9e19-d7d538412042', 'https://www.mycancergenome.org/content/clinical_trials/NCT02013154', 'A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab', '11717967-8881-51cf-a961-88598085ee04', ' NCT02013154', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma'], ['dc079969-9043-5f4d-af91-57931a18eb8f', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, WNT-Activated, Medulloblastoma, SHH-Activated"
20e3d8de-fee4-5710-9a2f-145210efff46,https://www.mycancergenome.org/content/alteration/tp53-r213l/,TP53 R213L," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['92888025-0cce-5e87-82f6-67004081fea6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '20e3d8de-fee4-5710-9a2f-145210efff46', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
72131208-da0f-5c55-99a3-c88e15ed0a71,https://www.mycancergenome.org/content/alteration/tp53-r249m/,TP53 R249M," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['43092bc5-b3db-5ce5-ab96-f302057e397d', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '72131208-da0f-5c55-99a3-c88e15ed0a71', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
bc65d8c8-e567-5949-af0f-81f840377a28,https://www.mycancergenome.org/content/alteration/tp53-s127y/,TP53 S127Y," Non-Small Cell Lung Carcinoma, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Malignant Solid Tumor, Lung Adenocarcinoma",, 1, 0,"[['5518a982-5ff1-509e-96f7-6d17bdc3a55f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'bc65d8c8-e567-5949-af0f-81f840377a28', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
854b04ef-860e-5032-b50c-b5a060ed67ae,https://www.mycancergenome.org/content/alteration/tp53-y220c/,TP53 Y220C," Malignant Breast Neoplasm, Non-Small Cell Lung Carcinoma, Malignant Ovarian Neoplasm, Hepatocellular Carcinoma, Squamous Cell Lung Carcinoma, Breast Ductal Carcinoma, Malignant Solid Tumor",, 1, 0,"[['62ffef8e-2268-5b72-a675-c67edb7e3044', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', '854b04ef-860e-5032-b50c-b5a060ed67ae', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor']]", None
7dee88b4-961c-53a3-b563-e2846809c859,https://www.mycancergenome.org/content/alteration/tp53-a119g/,TP53 A119G, None,,,,, None
20136a06-08ff-5b24-b177-42291df5b683,https://www.mycancergenome.org/content/alteration/tp53-a138p/,TP53 A138P, None,,,,, None
6ad6a957-ce71-59e3-b9c6-b8a6db9d5c4e,https://www.mycancergenome.org/content/alteration/tp53-a138v/,TP53 A138V, None,,,,, None
04059791-188f-5507-a141-41756021cb9e,https://www.mycancergenome.org/content/alteration/tp53-a159d/,TP53 A159D, None,,,,, None
8127c4d0-4f76-52a3-8c0f-482ac205712d,https://www.mycancergenome.org/content/alteration/tp53-a159p/,TP53 A159P, None,,,,, None
ec85f991-429a-55c0-9ade-fc7c5d2b93f4,https://www.mycancergenome.org/content/alteration/tp53-a159v/,TP53 A159V, None,,,,, None
cfbd00b2-3cc2-5ab1-a645-e64d44f68dcf,https://www.mycancergenome.org/content/alteration/tp53-a161d/,TP53 A161D, None,,,,, None
7af531a2-228f-566d-b2b7-aa9333a600c2,https://www.mycancergenome.org/content/alteration/tp53-a161s/,TP53 A161S, None,,,,, None
""
,Link,Biomarkers,Diseases,Pathways,Clinical_Trials,Drugs,ClinicalTrialsTitle,Alteration_Groups
c76e588f-080a-5f4e-a338-955130da287d,https://www.mycancergenome.org/content/gene/tp53/,TP53," Cancer, Vaginal Carcinoma, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Neuroblastoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Transitional Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Large Cell Lung Carcinoma, Clear Cell Renal Cell Carcinoma, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Acute Lymphoblastic Leukemia, Vulvar Carcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Hepatocellular Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Pancreatic Ductal Adenocarcinoma, Lymphoma, Malignant Peritoneal Neoplasm, Malignant Bladder Neoplasm, Benign Fibrous Histiocytoma, Malignant Head and Neck Neoplasm, Acute Myeloid Leukemia, Malignant Solid Tumor, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Breast Ductal Carcinoma, Anal Carcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Fallopian Tube Neoplasm, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Colon Neuroendocrine Neoplasm, Histiocytic And Dendritic Cell Cancer, Urothelial Carcinoma, Malignant Ovarian Epithelial Tumor", Cell cycle control, 206, 3,"[['8920c079-a6c0-5fa5-b5f0-aadce7ec0867', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['559d2f86-2a79-5e97-8b86-cbf90fa17ba6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['b0b04d8b-edba-56eb-9e00-1b5a069e185c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['c927ab37-1d1d-5755-a154-c18253fd367c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['686de7ed-a069-5fbb-9d0b-849398d393d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['97d2d07b-8fb4-55a5-8fae-682c4a5a091b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['1d8ef049-8e73-57c1-a414-127323b655d8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['edeb4236-f82c-56ac-b5bb-a7b247a407d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['81d544bf-76fa-5126-8bc4-ae12ff849510', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['2891c7b5-4548-5bc3-8cc1-ce2024027b6c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['428ca4a8-a020-51fe-8ed8-d1ee814d4a6f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor'], ['ef049a6e-21af-54d6-b69f-cfc4ab9b484c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['f876db17-7031-590a-80b8-f05f6b93cc07', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['3c6ec96c-d51b-53d2-b5e7-abd3106c6254', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['d0a1923a-945e-5758-bad0-7d964e2242f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['47faa36b-f117-52a2-a0c7-4a748fa30bfa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['0634f789-b86b-571a-922b-51d066058198', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['37ae8aef-3ce7-5a6a-8f0d-37c04d0c9b32', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['f435a5bb-177c-5d46-b831-b10d177b9d8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['bc6695f6-352a-5dd5-94b6-5b9dc00fd71a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2efa4aac-8164-5bff-a495-6626467a2375', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['8104b769-6031-50d3-b783-7379c93cd6c0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['7ac4e91c-40fa-5342-b988-2af33f945e67', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['77e2ffd3-7719-58e6-a1f5-3759cf00b74e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['aa95ff76-4526-5f44-8e9a-61d09c518749', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['555105c4-6ee2-5266-904d-244146ba85dd', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['1e6a42d4-1d17-5c82-8efd-a17d01604406', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a26b4e11-e0b1-5036-978d-8465070587cb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3da6e26f-c7ec-5113-805b-80b7302eae6b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['f1e66d04-9749-5f61-97d1-424ae2704448', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['8290b969-52fd-5ab6-a2a3-1dd845c68233', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a27cb61-7185-5eaa-b87b-ae2ba0387fa6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['ae756cad-e710-556d-b5ef-5e22ca23ae04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d0a5d9a6-03a3-5abd-a01f-92a1e71e0984', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['cfe127b9-93ba-5b83-986a-5a2a6ecca130', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['ddc6a312-3031-53c5-965e-94ac74f8b6aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['403dc844-4a13-5dc9-8d44-8bc4aaa0ffb1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['0adf2c15-fc9b-5c1e-8a0d-2b60253f9b4d', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['cf8e4c89-da0d-5e84-97dd-c0f4646a4166', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['526098fa-0c19-5bac-b9ec-1d29111862ab', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e51fc27a-baaa-58b8-8df6-6c5b2f8d984c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['4d3e8616-9c78-5e7c-a1cd-393769c71c90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['df545b25-510a-5a03-882f-6026d5665f0b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['9b29392c-b012-51ea-88bc-4a024dfc2c07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma'], ['f94ad441-3d98-53ac-a220-858c6ea23745', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c3c0333f-9623-53d2-bd07-3558d3ad0247', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['d7166f7a-728e-5550-82f1-b6c76863f2aa', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6e6afa2f-0af9-5d89-80fe-3442ce365909', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['b37fb9cc-bf33-5e4a-8c7f-1284f96e0926', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['f25dfe3b-b863-5ca3-96e0-a07dc5aa7dd4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['7c6bd3fa-b534-5f32-913c-13efe09a988c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['46d8d3b9-c1ba-505c-8c0b-277178274475', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['23ba20e7-a04f-5f1e-b7c3-05a463a80d4c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['5395e287-c588-5e7d-9705-05cf7638f0be', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['2857f779-7074-5887-9fb5-17ee5d67ea79', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['8476f372-4407-577a-a1e5-10066857162e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['ed558021-a193-5cd4-a0f1-2dfec163d38e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma'], ['12d2c9ee-8d91-574a-97ee-8c3ac141e289', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['7d56363c-3ca4-5237-a7c7-cb9d80ae5608', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['4b4e37a4-3dcb-5af1-9205-88e209220850', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'c76e588f-080a-5f4e-a338-955130da287d', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts']]",
eba36364-821f-5f60-b93e-4857edc625ee,https://www.mycancergenome.org/content/alteration/tp53-loss/,TP53 Loss," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Thymoma, Myeloid Sarcoma, Intracranial Primitive Neuroectodermal Neoplasm, Basal Cell Carcinoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Desmoplastic/Nodular Medulloblastoma, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Squamous Cell Carcinoma, Leiomyosarcoma, Ovarian Serous Tumor, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Malignant Bladder Neoplasm, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Proneural Glioblastoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Medulloblastoma with Extensive Nodularity, Non-Hodgkin Lymphoma, Multiple Myeloma, Smoldering Plasma Cell Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Malignant Pancreatic Neoplasm, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Carcinoma, Large Cell/Anaplastic Medulloblastoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Malignant Colon Neoplasm, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Central Nervous System Neoplasm, Malignant Colorectal Neoplasm, Gastric Carcinoma, Malignant Lung Neoplasm, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 187, 0,"[['e221663b-5a35-5781-bbd3-acada7f46f8b', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['75cd3142-59f8-5caf-adab-dad872fbc7f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['7c32e385-22e4-5688-819c-4219039fda73', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['507a6b75-20dd-5e8d-abb2-b8196882db5c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['762c33e0-037f-553d-b2b4-c73d4af3b9d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['ca08e81b-64ec-5e41-b861-3d109aaed50a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4b2e40ed-67de-5c6c-9834-d80205751186', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['1f4561b8-5862-59fe-a960-ee52834e42c3', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['c64afea7-5389-5d3a-98f7-0d22257d5bad', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['58779054-877f-5d9e-a552-42ecde884ed0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['35a2a8e4-de0f-59af-b5dd-f26637c7c010', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6b268729-eb67-5362-bb67-d48a43d0e20e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a4621e3f-3a6e-51bd-9cd6-117a397a7a03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['19f47721-6769-514d-9ce5-a8647c3c7258', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['69481b88-9661-5764-9f6e-ff06e1afbca5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['2636aeed-9b11-55de-888e-4840f09a44df', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['2e51066e-ca32-5524-83a2-0f6ff1cd1cd6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['82575ecc-4aeb-5cdb-b9ce-aac82265f105', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['c0c1e6c1-eac2-5830-a7f1-2af3091f8b99', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5ef759a2-1f77-5835-a0a4-a9bd3ae96f03', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['9063a22a-c9e8-5ed5-a226-f08e49d1be47', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['6fbe5e54-7397-5c5a-afa2-b5f980f4d677', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['30396263-e633-5e5b-b2f9-e36d15940e39', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['c53a462b-1d08-54f5-bb73-df53c3f7caf5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['62d5ae16-1908-5a7d-93c4-adf601d0148f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['0a2d4906-7ff2-52da-aa03-879b446eb5d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['a3c95bdb-87df-5825-bcf4-3d547ca4a9b1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['5a92b405-dcbc-5857-bd97-16d00864c6fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['d6153efa-d93e-5939-9290-a4fddd864cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['4153cbc8-adb3-556b-a0ea-195e9a842928', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['6c369150-0ca4-5ea1-8c34-0efaea36c614', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['d8777ca4-4beb-59d6-97df-02633de11587', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['1e8bd600-5a56-54a2-9f95-861a142ea82f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['510aaf02-415b-58c8-b95b-a6ed6e122e68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4c8949f0-9984-5c33-a764-737c02d3d529', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['24ba6965-b932-5e56-a39d-7c688648f3d7', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f7b4e5ac-0098-50ef-a807-85c14ad681c2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['92f18279-c687-5cc4-b720-47734b22ae3f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['f4aa0065-93a7-582f-b025-98d3908c5a94', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['f5ffe9a2-2a95-5e84-8469-51090a0449a1', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['f001c121-0641-5df9-81ce-a209ccbdcb07', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['251b9e77-7989-55ff-b71a-12c3a0c97083', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3e54bc33-a75f-50a6-9a3f-699b9c7f6685', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['4caa5049-8cfd-5822-95dd-80adf34b8341', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['6ceb47fd-d396-5eca-b527-ea6c61e2119b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['c63b1222-783c-578f-bf08-2290574e900b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['179a8789-afeb-5502-a57a-770cbf30db55', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['81bff8b8-6fac-5a5c-8e81-27395eea14bc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['885d536c-f17f-5837-b8fa-ce13bcc4992f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['4d1b46b7-1239-5840-b608-4590bfc2178e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['d373e6e1-5bd3-5f83-8b42-799026988bf1', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['f596dded-3c13-54d2-afcc-5940bfac2c69', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['46854f60-ad43-51de-9af3-25d368ee1488', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['020c7ed4-e01c-543b-b728-62c2768fdb51', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['2c32d193-1165-5ad8-9dbb-303619d8a194', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['a67abb46-6efa-5c25-978c-90b72f708423', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['583c481f-5151-5f2c-af2c-82a6fb53c0d6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['21d7eab8-2c4d-5418-976f-4f2a2c800b1b', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['316a53ff-e67c-57e5-a376-357b288d5bb7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['0d2eeb41-053d-5aa6-b0ac-a82c1e023a3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', 'eba36364-821f-5f60-b93e-4857edc625ee', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), ELN Adverse Risk Group, Medulloblastoma, SHH-Activated"
0abac394-06e2-5d38-8845-8aca7485d7b5,https://www.mycancergenome.org/content/alteration/tp53-mutation/,TP53 Mutation," Cancer, Pancreatic Adenocarcinoma, Small Cell Lung Carcinoma, Medulloblastoma, Primary Peritoneal Serous Adenocarcinoma, Anaplastic Oligoastrocytoma, Prolymphocytic Leukemia, Myeloid Sarcoma, Neuroblastoma, Myelodysplastic/Myeloproliferative Neoplasm, Head and Neck Squamous Cell Carcinoma, Myeloid Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, Hodgkin Lymphoma, Tongue Squamous Cell Carcinoma, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, High Grade Ovarian Serous Adenocarcinoma, Uterine Carcinosarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Malignant Prostate Neoplasm, Chronic Myelomonocytic Leukemia-0, Glioblastoma, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Esophageal Adenocarcinoma, Malignant Cervical Neoplasm, Esophageal Squamous Cell Carcinoma, Ovarian Serous Tumor, Malignant Hypopharyngeal Neoplasm, Refractory Anemia with Excess Blasts, Squamous Cell Lung Carcinoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Pancreatic Carcinoma, Kidney Carcinoma, Ovarian Serous Adenocarcinoma, Chronic Myelomonocytic Leukemia, Primary Peritoneal Carcinoma, Lymphoma, Benign Fibrous Histiocytoma, Malignant Solid Tumor, Acute Myeloid Leukemia, WHO Grade III Glioma, Osteosarcoma, Ovarian Carcinoma, Leukemia, Ovarian Endometrioid Adenocarcinoma, Bladder Carcinoma, Chronic Lymphocytic Leukemia, Fallopian Tube Endometrioid Adenocarcinoma, Chronic Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Sarcoma, Pharyngeal Squamous Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Melanoma, Malignant Breast Neoplasm, Breast Carcinoma, Malignant Testicular Neoplasm, Prostate Adenocarcinoma, Lung Adenocarcinoma, Endometrial Carcinoma, Myelodysplastic Syndromes, Non-Small Cell Lung Carcinoma, Colon Carcinoma, Malignant Ovarian Neoplasm, Prostate Carcinoma, Gastric Adenocarcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Adrenal Gland Cancer, Malignant Skin Neoplasm, Colorectal Carcinoma, Colorectal Adenocarcinoma, Head and Neck Carcinoma, Fallopian Tube Carcinoma, Mantle Cell Lymphoma, High Grade Fallopian Tube Serous Adenocarcinoma, Malignant Colorectal Neoplasm, Gastric Carcinoma, Ovarian Clear Cell Adenocarcinoma, Urothelial Carcinoma",, 175, 0,"[['f7b78afe-1dc1-544b-86ca-fc303608fe12', 'https://www.mycancergenome.org/content/clinical_trials/NCT05001828', 'Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT05001828', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['3a06b6c1-b916-585e-a8ee-bf0d44603555', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['d401d6ac-02de-5e98-9416-db7a5d609cae', 'https://www.mycancergenome.org/content/clinical_trials/NCT04734990', 'Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04734990', ' Phase 1/Phase 2', ' ASXL1, ASXL1 Loss, ASXL1 Mutation,', ' Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndromes'], ['11bbc0c7-e808-5c5b-b9a4-34854b768042', 'https://www.mycancergenome.org/content/clinical_trials/NCT04708054', 'Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04708054', ' Phase 2', ' ABL1, ARAF, ARAF Mutation,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes'], ['ecfb2c62-17f7-5a23-b492-04243f363a68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04660045', 'Early Intervention With Acalabrutinib in Patients With High Risk CLL', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04660045', ' Phase 2', ' Complex karyotype, MYC,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['50a3a24a-ffba-56d3-b0f4-dd00e66878f5', 'https://www.mycancergenome.org/content/clinical_trials/NCT04659616', 'Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04659616', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['144034da-587c-5a5c-91b8-88ba48987da8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04644016', 'Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04644016', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['16bf36af-4f2b-51ae-a6b8-b1a112e0d541', 'https://www.mycancergenome.org/content/clinical_trials/NCT04638309', 'APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04638309', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Myelodysplastic Syndromes'], ['92dbd658-5154-5f7c-bdac-452374dadf04', 'https://www.mycancergenome.org/content/clinical_trials/NCT04592237', 'Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04592237', ' Phase 2', ' PTEN, PTEN Loss, PTEN Mutation,', ' Prostate Carcinoma'], ['4c48bf2b-8585-59aa-84c1-fed10995262c', 'https://www.mycancergenome.org/content/clinical_trials/NCT04571645', 'Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04571645', ' Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['41d02d3c-8e93-5775-bc6d-2ba1db0df6b0', 'https://www.mycancergenome.org/content/clinical_trials/NCT04526288', 'CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04526288', ' Phase 2', ' CBL, CBL Loss, CBL Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Myeloid Neoplasm'], ['a9a7590f-c952-5fa5-899a-8d504e6636a6', 'https://www.mycancergenome.org/content/clinical_trials/NCT04510584', 'Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04510584', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma'], ['a778f5c1-738a-5249-b3e5-e2dfc385fc21', 'https://www.mycancergenome.org/content/clinical_trials/NCT04476199', 'Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04476199', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome'], ['bceb75d4-b0e0-5d7c-ba19-d88de862ad90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04425655', 'Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04425655', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['6937de14-2dcc-5474-8d7e-c5f91fb0574f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04388852', 'DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04388852', ' Phase 1', ' PTEN, PTEN Deficient Expression,', ' Clear Cell Renal Cell Carcinoma, Prostate Carcinoma, Urothelial Carcinoma'], ['f11de56c-83c2-509d-8d13-4966c0a84f68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04383938', 'Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04383938', ' Phase 1/Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Adenocarcinoma of the Gastroesophageal Junction, Bladder Carcinoma, Gastric Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Urothelial Carcinoma'], ['2cab8bcd-e3e2-5b6e-87ac-957239cf2b90', 'https://www.mycancergenome.org/content/clinical_trials/NCT04326439', 'AflacLL1901 (CHOA-AML)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04326439', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['e52b77a9-4cb6-5fef-af5a-1fb74e535e3a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293562', 'A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293562', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['baf71877-bdd1-5a51-932c-ea31959c69ca', 'https://www.mycancergenome.org/content/clinical_trials/NCT04293094', 'Study of AMG 650 in Adult Participants With Advanced Solid Tumors', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04293094', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Endometrial Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Primary Peritoneal Serous Adenocarcinoma'], ['cb33e472-26d3-5149-8ca1-2b1218c5c31b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04277442', 'Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04277442', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['22241703-06ed-5c36-a6fc-4f16f183620b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04262843', 'Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04262843', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['1557f2bc-b966-526c-86c9-4fbee1673216', 'https://www.mycancergenome.org/content/clinical_trials/NCT04234061', 'Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04234061', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Mantle Cell Lymphoma'], ['f6845d6d-32cc-5e48-950b-a2efb5bb76db', 'https://www.mycancergenome.org/content/clinical_trials/NCT04232241', 'Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04232241', ' Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['084c7c78-ac7a-5cb2-8307-dd942e9cd182', 'https://www.mycancergenome.org/content/clinical_trials/NCT04220684', 'Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04220684', ' Phase 1', ' TET2, TET2 Loss, TET2 Mutation,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['d7051af7-76a0-5bf9-8400-b10751bccf68', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214860', 'APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214860', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia'], ['4fd06ce5-42bf-522f-8fcc-8eabcce71cea', 'https://www.mycancergenome.org/content/clinical_trials/NCT04214626', 'R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04214626', ' Phase 2', ' BCL2 Expression, MYC Expression,', ' Diffuse Large B-Cell Lymphoma'], ['6aeabdb2-ae7c-5f4c-8084-53f8a1f439ac', 'https://www.mycancergenome.org/content/clinical_trials/NCT04187105', 'BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04187105', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['2b86b372-c022-50ab-88d9-972cbaff3f20', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167696', 'Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04167696', ' Phase 1', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['10a68846-4ac9-59cc-a7bc-0788ddd03d30', 'https://www.mycancergenome.org/content/clinical_trials/NCT04159155', 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04159155', ' Phase 2/Phase 3', ' TP53, TP53 Loss, TP53 Mutation', ' Endometrial Carcinoma, Endometrial Serous Adenocarcinoma'], ['c96141b1-b8c4-59fb-af26-5456e9fd0b42', 'https://www.mycancergenome.org/content/clinical_trials/NCT04146038', 'Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04146038', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm'], ['449c6899-31a7-519a-8457-d268af25043a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04128501', 'Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04128501', ' Phase 2', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T-Cell Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['f1785909-382a-5e02-8dde-ea38e6b0843a', 'https://www.mycancergenome.org/content/clinical_trials/NCT04106076', 'Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04106076', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia'], ['56c9a226-5136-5a14-8948-47aa7b60182e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04102020', 'A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04102020', ' Phase 3', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['29a19ae2-db0b-53e2-8a57-136850f3ac52', 'https://www.mycancergenome.org/content/clinical_trials/NCT04099966', 'AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04099966', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma'], ['5d892867-dbff-551b-8ada-59265af845a8', 'https://www.mycancergenome.org/content/clinical_trials/NCT04051996', 'GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04051996', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia'], ['5e54fb27-0e91-516c-9afd-c497eb96e45b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04010968', 'Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT04010968', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia'], ['01022853-10d1-5fe0-b6e7-05a02550d458', 'https://www.mycancergenome.org/content/clinical_trials/NCT03983850', 'Optimizing PTCy Dose and Timing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03983850', ' Phase 1/Phase 2', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Histiocytic and Dendritic Cell Neoplasm, Hodgkin Lymphoma, Mature T-Cell and NK-Cell Neoplasm, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis, T-Cell Acute Lymphoblastic Leukemia'], ['75467af3-5fe1-5e9f-b61c-687bc1f10aa2', 'https://www.mycancergenome.org/content/clinical_trials/NCT03931291', 'APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03931291', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['3875649e-f11b-559f-b059-04a2b0ee087a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03913026', 'UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03913026', ' Phase 2', ' ABL1, ABL1 Fusion, ABL2,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia'], ['90ac98da-ede6-524a-810b-98386352229e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03878927', 'CPX-351+GO in Subjects 55 Years Old, or Older, With AML', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03878927', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia'], ['14a7a77b-f7c5-5dfa-9675-d5d4bb667784', 'https://www.mycancergenome.org/content/clinical_trials/NCT03849651', 'TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03849651', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Biphenotypic Leukemia, Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloid Sarcoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Non-Hodgkin Lymphoma'], ['eee87161-3edc-530f-baba-ad74872676f3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03844815', 'Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03844815', ' Phase 1', ' Complex karyotype, DEK, DEK-NUP214 Fusion,', ' Acute Myeloid Leukemia'], ['08b0c502-82be-5e1d-80d6-e6686e97ccda', 'https://www.mycancergenome.org/content/clinical_trials/NCT03824483', 'Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03824483', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation', ' Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma'], ['ed961ae2-c10b-528d-9d0f-55f37a52e778', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['ce12c206-947d-5653-974b-d4191b4649db', 'https://www.mycancergenome.org/content/clinical_trials/NCT03699475', 'Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03699475', ' Phase 2/Phase 3', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Myelodysplastic Syndromes'], ['4eeebc62-194e-5fb3-bc14-ad8e21ba09ce', 'https://www.mycancergenome.org/content/clinical_trials/NCT03696537', 'IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03696537', ' Phase 1', ' 17pMDR (minimally deleted region),', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['53feb50a-6a0f-599a-a954-309fbe9a0de9', 'https://www.mycancergenome.org/content/clinical_trials/NCT03668340', 'AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03668340', ' Phase 2', ' TP53, TP53 Deficient Expression,', ' Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma'], ['a7a4a697-71d5-54c5-95e7-85092d33c719', 'https://www.mycancergenome.org/content/clinical_trials/NCT03613532', 'Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03613532', ' Phase 1', ' ABL1, ASXL1, ASXL1 Loss,', ' Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome'], ['e36e66ab-7a85-5362-bbeb-4cf163baacb3', 'https://www.mycancergenome.org/content/clinical_trials/NCT03612739', 'EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03612739', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory Anemia with Excess Blasts'], ['bfebf10b-d14b-549b-a038-d12227a0698e', 'https://www.mycancergenome.org/content/clinical_trials/NCT03588078', 'Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03588078', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Anemia with Excess Blasts'], ['8ab4d815-2021-5168-9698-9562844d44f6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03574402', 'Phase II Umbrella Study Directed by Next Generation Sequencing', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03574402', ' Phase 2', ' BCL2L11, BCL2L11 Deletion,', ' Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma'], ['3c4e65b7-ec15-5774-95d5-49e9e37661fe', 'https://www.mycancergenome.org/content/clinical_trials/NCT03567642', 'A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03567642', ' Phase 1', ' EGFR, EGFR A763_Y764insFQEA (somatic),', ' Non-Small Cell Lung Carcinoma'], ['b7b55cf4-1a82-58c2-92a0-9b9c171b6d84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03533816', 'Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03533816', ' Phase 1', ' ABL1, AFF1, ASXL1, ASXL1 Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes'], ['aceef024-5e37-51c3-9933-c07d372fff13', 'https://www.mycancergenome.org/content/clinical_trials/NCT03531736', 'T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03531736', ' Phase 1', ' ABL1, ABL1 T315I, AFF1,', ' Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma'], ['283939cc-045c-583b-8586-c76358cdff5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03530683', 'A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03530683', ' Phase 1', ' TP53, TP53 Loss, TP53 Mutation', ' Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma'], ['36ed3b2a-14bf-5c6a-99eb-4b4891340959', 'https://www.mycancergenome.org/content/clinical_trials/NCT03494569', 'Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03494569', ' Phase 1', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia'], ['32413726-a315-5b7a-9b0c-d0b7e4efe582', 'https://www.mycancergenome.org/content/clinical_trials/NCT03466320', 'DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03466320', ' Phase 1/Phase 2', ' Complex karyotype, Loss of Y,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['9df9fe36-0475-5beb-bb1b-ea38618261b4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03455517', 'Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03455517', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['6b105b72-f072-51af-a694-bca48a81fc74', 'https://www.mycancergenome.org/content/clinical_trials/NCT03454984', 'SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03454984', ' Phase 2', ' Complex karyotype, MECOM,', ' Acute Myeloid Leukemia, Myelodysplastic Syndromes'], ['45176428-ba01-57ec-93bf-a627b91c9d44', 'https://www.mycancergenome.org/content/clinical_trials/NCT03439371', 'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia', '0abac394-06e2-5d38-8845-8aca7485d7b5', ' NCT03439371', ' Phase 2', ' ABL1, AFF1, BCR, BCR-ABL1 Fusion,', ' Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts']]"," NCCN 2016 Poor Risk AML, TP53 Mutation Exclusion, del(13q) AND TP53 Mutation (-), RB1 Mutation AND TP53 Mutation, ELN Adverse Risk Group"
c4073622-6381-5451-bfc5-0dc4d8f52685,https://www.mycancergenome.org/content/alteration/tp53-nonsense/,TP53 Nonsense," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['447f5fc0-9755-5554-9489-52bf792f5e5a', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['aed89f36-2dff-5e7a-9f3b-9694d21ff13c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['6c53b51c-ec0b-5963-be34-724106c30d40', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9b7526ff-6ce4-5147-972b-15c1d50cd667', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['7175024c-3075-5e83-ac67-913a6cef02da', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['f8f4db5c-b2b4-5bc8-b49a-ed430280f5ad', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['48f6a3a9-0168-55ba-bdab-650edb0c22c1', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['76893720-4f00-56f2-a36d-96319e39d6e3', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['0730948e-03fe-5b5a-b69c-b52ad0d99b62', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['693e3850-fbbb-5b63-bd6a-a160f9c427d2', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['0336585b-cdc2-5db7-b929-4e2de4341cb8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['a572b921-9c3e-5c8d-9334-28ce340d7721', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['f769fae4-c2db-56b1-8f68-2078597fcdf7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['72abd7ae-4680-5b64-a09b-380d5bd6bd2c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['dfa8f137-1a3b-568d-b0a3-092e25ba1e85', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'c4073622-6381-5451-bfc5-0dc4d8f52685', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
269b555a-95a5-5802-b6bb-c0a8c811507d,https://www.mycancergenome.org/content/alteration/tp53-c-1-c-137-missense/,TP53 c.1-c.137 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['c27e1b05-4b8a-5f12-b857-e86effb7b653', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['1e4d65ff-ce6b-5d92-9939-554bfb2e005a', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c8bc5be2-ea2d-576e-84b4-6aa027f56c49', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '269b555a-95a5-5802-b6bb-c0a8c811507d', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
3c6b1ac9-059f-5f3d-88bd-06d37472dd11,https://www.mycancergenome.org/content/alteration/tp53-c-142-c-212-missense/,TP53 c.142-c.212 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['659fd00d-ad10-56e6-b893-43e8f47719b7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['7ea0ac07-9f00-59fb-895a-094e1d5c2c27', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['c9a756fc-ae49-567a-be17-8988dd44867c', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '3c6b1ac9-059f-5f3d-88bd-06d37472dd11', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
7407edb4-03c5-5b25-ba9b-8742d62bc94e,https://www.mycancergenome.org/content/alteration/tp53-c-217-c-1178-missense/,TP53 c.217-c.1178 Missense," Myelodysplastic Syndromes, Vaginal Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia, Penile Carcinoma, Vulvar Carcinoma, Chronic Lymphocytic Leukemia, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma",, 3, 3,"[['0629feba-d546-551e-b654-26f8bf9bfb92', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['a81fed8c-56f7-5f85-a75c-fa670584a139', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['7bc76597-92a2-5f63-a41d-9c48908cbb7e', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', '7407edb4-03c5-5b25-ba9b-8742d62bc94e', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
eb6b3698-fb12-5db0-94a0-2b65a7a1096f,https://www.mycancergenome.org/content/alteration/tp53-frameshift/,TP53 Frameshift," Ovarian Carcinoma, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Vaginal Carcinoma, Non-Small Cell Lung Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Carcinoma, Acute Lymphoblastic Leukemia, Head and Neck Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia, Penile Carcinoma, Colorectal Carcinoma, Vulvar Carcinoma, Anal Carcinoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 16, 3,"[['773b840d-a0bf-54fa-8055-a2d50fd402d0', 'https://www.mycancergenome.org/content/clinical_trials/NCT03745716', 'APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03745716', ' Phase 3', ' TP53, TP53 Frameshift, TP53 Nonsense,', ' Myelodysplastic Syndromes'], ['74e18afb-e0b6-5215-ba31-65ed711ed2f4', 'https://www.mycancergenome.org/content/clinical_trials/NCT03204188', 'Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03204188', ' Phase 2', ' Complex karyotype, NOTCH1,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['e8ec27f2-cfb1-589b-b983-0b6963e9b98c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03104270', 'Combination Study for High Risk Multiple Myeloma Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03104270', ' Phase 2', ' IGH, IGH-MAF Fusion, IGH-MAFB Fusion,', ' Multiple Myeloma, Plasma Cell Leukemia'], ['9a68f134-c3ed-58de-8d6e-d7faf3634ae7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03096054', 'A CR-UK Phase I Trial of LY3143921', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT03096054', ' Phase 1', ' ER Negative, ER No Expression,', ' Breast Carcinoma, Colorectal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Pancreatic Carcinoma, Squamous Cell Lung Carcinoma, Urothelial Carcinoma'], ['91d83c6b-d3b5-5180-adbf-f152b0873091', 'https://www.mycancergenome.org/content/clinical_trials/NCT02906332', 'Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02906332', ' Phase 2', ' FGFR3, Hypodiploidy, IGH,', ' Multiple Myeloma'], ['bdc5b528-c2bc-5ea1-a27a-cc6a20456106', 'https://www.mycancergenome.org/content/clinical_trials/NCT02869633', 'Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02869633', ' Phase 2', ' NOTCH1, NOTCH1 Loss, NOTCH1 Mutation,', ' Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma'], ['7a3433d3-8a60-5ae6-bf27-caeb622041e9', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797977', 'A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797977', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Anal Carcinoma, Cervical Carcinoma, High Grade Ovarian Serous Adenocarcinoma, Malignant Solid Tumor, Penile Carcinoma, Soft Tissue Sarcoma, Vaginal Carcinoma, Vulvar Carcinoma'], ['f48415b8-7785-5024-8dc2-85513f4246a7', 'https://www.mycancergenome.org/content/clinical_trials/NCT02797964', 'A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02797964', ' Phase 1/Phase 2', ' ARID1A, ARID1A Loss, ARID1A Mutation,', ' Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Carcinoma, Prostate Carcinoma'], ['75e44dd3-0602-570f-ab4d-ae1c844171ec', 'https://www.mycancergenome.org/content/clinical_trials/NCT02756897', 'Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02756897', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['4f4946c7-fa0e-59d2-a0b9-e39cce7a1c30', 'https://www.mycancergenome.org/content/clinical_trials/NCT02633059', 'Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02633059', ' Phase 1/Phase 2', ' Monosomy 17, Nullisomy 17,', ' Multiple Myeloma'], ['2a2e1ee8-7914-51be-9c9b-d2cfee7eb3c8', 'https://www.mycancergenome.org/content/clinical_trials/NCT02481297', 'Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02481297', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['09b9b4fb-7857-5fb3-b894-07c79a60c625', 'https://www.mycancergenome.org/content/clinical_trials/NCT02406742', 'A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02406742', ' Phase 1/Phase 2', ' Complex karyotype, TP53,', ' Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['05d7ba44-424c-58f0-982e-3e6916ccfe2f', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia'], ['028ae3ba-5023-51d4-9dd3-1f96ca814984', 'https://www.mycancergenome.org/content/clinical_trials/NCT02007044', 'Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT02007044', ' Phase 2', ' TP53, TP53 Frameshift, TP53 Loss,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Prolymphocytic Leukemia'], ['517b5a62-0025-58b4-a78d-dfd21f9c36cf', 'https://www.mycancergenome.org/content/clinical_trials/NCT01204164', 'Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies', 'eb6b3698-fb12-5db0-94a0-2b65a7a1096f', ' NCT01204164', ' Phase 1', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes']]"," TP53 Frameshift, Nonsense, or Missesense Mutations, del(11q), del(17p), or TP53 Missense Mutations"
c07a00ba-8a73-55f4-9c19-2fa957a8d589,https://www.mycancergenome.org/content/alteration/del-17-p13/,del(17)(p13)," Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",, 8, 3,"[['6fd5916f-f91a-55db-846a-b2245ff3ac60', 'https://www.mycancergenome.org/content/clinical_trials/NCT04778397', ""Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia"", 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT04778397', ' Phase 3', ' TP53, TP53 Loss, TP53 Mutation,', ' Acute Myeloid Leukemia'], ['65deaa23-b44d-5d89-8cbf-6a648e1dc914', 'https://www.mycancergenome.org/content/clinical_trials/NCT03943342', 'Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03943342', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia'], ['d293694e-f99f-573b-b2db-e4b36f2a4842', 'https://www.mycancergenome.org/content/clinical_trials/NCT03734198', 'Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03734198', ' Phase 2', ' TP53, TP53 Loss, TP53 Mutation,', ' Chronic Lymphocytic Leukemia'], ['b4c0208e-2e42-5ba3-8ba1-f30f644087c7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03683277', 'IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03683277', ' Phase 2', ' FGFR3, IGH, IGH-FGFR3 Fusion,', ' Multiple Myeloma'], ['a5d10f7a-517f-599c-bcb9-e2f5b8507ef7', 'https://www.mycancergenome.org/content/clinical_trials/NCT03625388', 'Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT03625388', ' Phase 2', ' ABL1, BCR, BCR-ABL1 Fusion,', ' Chronic Myeloid Leukemia'], ['616c00cc-7fcb-5879-8d95-0269a4730a9b', 'https://www.mycancergenome.org/content/clinical_trials/NCT02518555', 'Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02518555', ' Phase 2', ' Complex karyotype, Very Complex karyotype,', ' Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'], ['5e60ba9f-207f-5696-8efa-14fdd2c1991d', 'https://www.mycancergenome.org/content/clinical_trials/NCT02169791', 'Nonmyeloablative Haploidentical Transplant Followed by MLN9708', 'c07a00ba-8a73-55f4-9c19-2fa957a8d589', ' NCT02169791', ' Phase 2', ' ABL1, AFF1, ATM, ATM Loss,', ' Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Prolymphocytic Leukemia']]"," 17p deletion group, del(11q), del(17p), or TP53 Missense Mutations"
edbc8f44-837f-5e73-9dae-161f44017d50,https://www.mycancergenome.org/content/alteration/tp53-codon-175-missense/,TP53 Codon 175 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['584f0cb2-196d-50cf-8571-5183f415f224', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', 'edbc8f44-837f-5e73-9dae-161f44017d50', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0dfd0073-1d59-5dce-b737-26b8fcdbe9ea,https://www.mycancergenome.org/content/alteration/tp53-codon-245-missense/,TP53 Codon 245 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['dc34c37f-0367-5489-9b23-cb1d28661739', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0dfd0073-1d59-5dce-b737-26b8fcdbe9ea', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
5aef6155-30cc-59d4-a900-af7b056d3c3e,https://www.mycancergenome.org/content/alteration/tp53-codon-248-missense/,TP53 Codon 248 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['0afacc31-c762-5ebb-bb29-30664eb6fbc5', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '5aef6155-30cc-59d4-a900-af7b056d3c3e', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
6ff8e186-58ca-5ded-98cd-228789184f15,https://www.mycancergenome.org/content/alteration/tp53-codon-273-missense/,TP53 Codon 273 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['f87e24bd-f06e-5fa0-bdb8-24b838509e84', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '6ff8e186-58ca-5ded-98cd-228789184f15', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
0ac59bdc-e47b-5e50-b8c2-856d5a528bd8,https://www.mycancergenome.org/content/alteration/tp53-codon-282-missense/,TP53 Codon 282 Missense," Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction",, 1, 0,"[['8e886948-d266-5c63-926a-8c04ab73b6af', 'https://www.mycancergenome.org/content/clinical_trials/NCT03641313', 'Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer', '0ac59bdc-e47b-5e50-b8c2-856d5a528bd8', ' NCT03641313', ' Phase 2', ' TP53, TP53 Codon 175 Missense,', ' Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma']]", None
9fe84676-1bef-5cdc-95c3-c33f9658209f,https://www.mycancergenome.org/content/alteration/tp53-k132e/,TP53 K132E," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['148b646c-d6b4-59c7-a3e9-efbf1ac76504', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '9fe84676-1bef-5cdc-95c3-c33f9658209f', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
f60c488b-723e-5350-9c5b-d446d1f06e17,https://www.mycancergenome.org/content/alteration/tp53-k132n/,TP53 K132N," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['6dfa7e28-f1fc-5a15-aee9-7edfa1184520', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'f60c488b-723e-5350-9c5b-d446d1f06e17', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
6c2f74c4-62ff-5a6f-9bee-12723a40c35c,https://www.mycancergenome.org/content/alteration/tp53-mutation-germline/,TP53 Mutation (germline)," Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 8, 0,"[['e19c8958-eb02-52ca-bab7-53f3124d8153', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['e0f0c0f4-1363-53e8-899f-3e2d79718c6e', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['c7a91999-5725-55bd-83d1-7c209364e848', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['5c3cfa58-e935-5fc1-a630-258099566f11', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['29323168-40ca-5422-ab24-b1061b7229f8', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['eca0ca48-eac3-527d-8f54-a1729ec5c75c', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['f96380a3-fd32-5ebf-868d-5596fae3254c', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['519bcf36-7c4d-5c6c-bf85-b245f1d57ced', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '6c2f74c4-62ff-5a6f-9bee-12723a40c35c', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, SHH-Activated"
11717967-8881-51cf-a961-88598085ee04,https://www.mycancergenome.org/content/alteration/tp53-mutation-somatic/,TP53 Mutation (somatic)," Desmoplastic/Nodular Medulloblastoma, Gastric Adenocarcinoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Intracranial Primitive Neuroectodermal Neoplasm",, 11, 0,"[['3b63dd08-f5ba-58b4-8b8d-f85a8d7e528f', 'https://www.mycancergenome.org/content/clinical_trials/NCT04696029', 'DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04696029', ' Phase 2', ' CDK6, CDK6 Amplification,', ' Medulloblastoma'], ['022e5e3a-262c-5e1c-843f-15f420b2624b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04474964', 'Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.', '11717967-8881-51cf-a961-88598085ee04', ' NCT04474964', ' N/A', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['c9ca4d40-cff8-5c8b-b27e-9a666a82f338', 'https://www.mycancergenome.org/content/clinical_trials/NCT04402073', 'Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04402073', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, WNT-Activated'], ['7fd24b12-032f-51e0-a186-6362520513b2', 'https://www.mycancergenome.org/content/clinical_trials/NCT04167618', '177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT04167618', ' Phase 1/Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma'], ['32cc1a7a-4e80-591e-9047-3c483dea866b', 'https://www.mycancergenome.org/content/clinical_trials/NCT04023669', 'Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT04023669', ' Phase 1', ' CDK6, CDK6 Amplification,', ' Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated'], ['c9ab85ca-9b50-56bb-be65-7d5229f9c9fc', 'https://www.mycancergenome.org/content/clinical_trials/NCT03904862', 'Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery', '11717967-8881-51cf-a961-88598085ee04', ' NCT03904862', ' Phase 1/Phase 2', ' DDX3X, DDX3X Loss, DDX3X Mutation,', ' Medulloblastoma'], ['4f7f8a46-7499-583b-b7b9-813aae4d42fb', 'https://www.mycancergenome.org/content/clinical_trials/NCT03434262', ""SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors"", '11717967-8881-51cf-a961-88598085ee04', ' NCT03434262', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Anaplastic Astrocytoma, Anaplastic Astrocytoma, IDH-Mutant, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, Anaplastic Pleomorphic Xanthoastrocytoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Diffuse Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Ependymoma, Ependymoma, RELA Fusion-Positive, Glioblastoma, High-Grade Glioma, NOS, Malignant Glioma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, SHH-Activated, Medulloblastoma, WNT-Activated, Medulloepithelioma'], ['7400aefa-8a50-5e85-9e3d-1e8a61c86384', 'https://www.mycancergenome.org/content/clinical_trials/NCT02875314', 'HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors', '11717967-8881-51cf-a961-88598085ee04', ' NCT02875314', ' Phase 4', ' APC, APC Loss, APC Mutation (germline),', ' Central Nervous System Embryonal Neoplasm, Central Nervous System Ganglioneuroblastoma, Central Nervous System Neuroblastoma, Desmoplastic/Nodular Medulloblastoma, Large Cell/Anaplastic Medulloblastoma, Medulloblastoma, Medulloblastoma with Extensive Nodularity, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Pineoblastoma'], ['6018fcaf-b49b-51c5-b441-4e8bd9bc9711', 'https://www.mycancergenome.org/content/clinical_trials/NCT02724579', 'Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT02724579', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Medulloblastoma, Medulloblastoma, WNT-Activated'], ['3b6b479e-8f1e-58b2-9e19-d7d538412042', 'https://www.mycancergenome.org/content/clinical_trials/NCT02013154', 'A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab', '11717967-8881-51cf-a961-88598085ee04', ' NCT02013154', ' Phase 1', ' APC, APC Loss, APC Mutation (germline),', ' Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma'], ['dc079969-9043-5f4d-af91-57931a18eb8f', 'https://www.mycancergenome.org/content/clinical_trials/NCT01878617', 'A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma', '11717967-8881-51cf-a961-88598085ee04', ' NCT01878617', ' Phase 2', ' APC, APC Loss, APC Mutation (germline),', ' Intracranial Primitive Neuroectodermal Neoplasm, Medulloblastoma']]"," Medulloblastoma, WNT-Activated, Medulloblastoma, SHH-Activated"
20e3d8de-fee4-5710-9a2f-145210efff46,https://www.mycancergenome.org/content/alteration/tp53-r213l/,TP53 R213L," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['92888025-0cce-5e87-82f6-67004081fea6', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '20e3d8de-fee4-5710-9a2f-145210efff46', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
72131208-da0f-5c55-99a3-c88e15ed0a71,https://www.mycancergenome.org/content/alteration/tp53-r249m/,TP53 R249M," Colorectal Carcinoma, Malignant Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Carcinoma",, 1, 0,"[['43092bc5-b3db-5ce5-ab96-f302057e397d', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', '72131208-da0f-5c55-99a3-c88e15ed0a71', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
bc65d8c8-e567-5949-af0f-81f840377a28,https://www.mycancergenome.org/content/alteration/tp53-s127y/,TP53 S127Y," Non-Small Cell Lung Carcinoma, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Malignant Solid Tumor, Lung Adenocarcinoma",, 1, 0,"[['5518a982-5ff1-509e-96f7-6d17bdc3a55f', 'https://www.mycancergenome.org/content/clinical_trials/NCT03953235', 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens', 'bc65d8c8-e567-5949-af0f-81f840377a28', ' NCT03953235', ' Phase 1/Phase 2', ' BRAF, BRAF G466V, CTNNB1,', ' Colorectal Carcinoma, Malignant Solid Tumor, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma']]", None
854b04ef-860e-5032-b50c-b5a060ed67ae,https://www.mycancergenome.org/content/alteration/tp53-y220c/,TP53 Y220C," Malignant Breast Neoplasm, Non-Small Cell Lung Carcinoma, Malignant Ovarian Neoplasm, Hepatocellular Carcinoma, Squamous Cell Lung Carcinoma, Breast Ductal Carcinoma, Malignant Solid Tumor",, 1, 0,"[['62ffef8e-2268-5b72-a675-c67edb7e3044', 'https://www.mycancergenome.org/content/clinical_trials/NCT04585750', 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', '854b04ef-860e-5032-b50c-b5a060ed67ae', ' NCT04585750', ' Phase 1/Phase 2', ' TP53, TP53 Y220C', ' Malignant Solid Tumor']]", None
7dee88b4-961c-53a3-b563-e2846809c859,https://www.mycancergenome.org/content/alteration/tp53-a119g/,TP53 A119G, None,,,,, None
20136a06-08ff-5b24-b177-42291df5b683,https://www.mycancergenome.org/content/alteration/tp53-a138p/,TP53 A138P, None,,,,, None
6ad6a957-ce71-59e3-b9c6-b8a6db9d5c4e,https://www.mycancergenome.org/content/alteration/tp53-a138v/,TP53 A138V, None,,,,, None
04059791-188f-5507-a141-41756021cb9e,https://www.mycancergenome.org/content/alteration/tp53-a159d/,TP53 A159D, None,,,,, None
8127c4d0-4f76-52a3-8c0f-482ac205712d,https://www.mycancergenome.org/content/alteration/tp53-a159p/,TP53 A159P, None,,,,, None
ec85f991-429a-55c0-9ade-fc7c5d2b93f4,https://www.mycancergenome.org/content/alteration/tp53-a159v/,TP53 A159V, None,,,,, None
cfbd00b2-3cc2-5ab1-a645-e64d44f68dcf,https://www.mycancergenome.org/content/alteration/tp53-a161d/,TP53 A161D, None,,,,, None
7af531a2-228f-566d-b2b7-aa9333a600c2,https://www.mycancergenome.org/content/alteration/tp53-a161s/,TP53 A161S, None,,,,, None
""
